ciprofloxacin has been researched along with Cystic Fibrosis in 224 studies
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.
ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.
Cystic Fibrosis: An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The sputum pharmacokinetics and clinical efficacy of ciprofloxacin in lower respiratory tract infections is reviewed." | 10.16 | Clinical efficacy of ciprofloxacin in lower respiratory tract infections. ( Pedersen, SS, 1989) |
| "The pharmacokinetic characteristics of ciprofloxacin were studied in 10 children with cystic fibrosis, aged from 6 to 16 years, who had completed the standard regimen of intravenous ceftazidime and amikacin." | 9.08 | Pharmacokinetics of ciprofloxacin in pediatric cystic fibrosis patients. ( Fischer, C; Hampel, B; Kuhlmann, J; Schaad, UB; Schaefer, HG; Stass, H; Wedgwood, J, 1996) |
| "/oral ciprofloxacin monotherapy offers a safe and efficacious alternative to standard parenteral therapy for acute pulmonary exacerbations in pediatric cystic fibrosis patients." | 9.08 | Sequential ciprofloxacin therapy in pediatric cystic fibrosis: comparative study vs. ceftazidime/tobramycin in the treatment of acute pulmonary exacerbations. The Cystic Fibrosis Study Group. ( Church, DA; Echols, RM; Haverstock, DC; Kanga, JF; Kuhn, RJ; Painter, BG; Perroncel, RY; Rubio, TT; Spohn, WA; Stevens, JC; Thurberg, BE, 1997) |
| "The efficacy and safety of oral ciprofloxacin as a maintenance antipseudomonal therapy were evaluated in 44 patients with cystic fibrosis who had completed a 14-day regimen of intensive hospital therapy with intravenous ceftazidime and amikacin, supplemented by amikacin inhalation therapy." | 9.08 | Ciprofloxacin as antipseudomonal treatment in patients with cystic fibrosis. ( Hampel, B; Kraemer, R; Ruedeberg, A; Schaad, UB; Wedgwood, J, 1997) |
| " This study examined the disposition of sequentially administered intravenous and oral ciprofloxacin, as well as provided dosing recommendations, for the treatment of acute pulmonary exacerbations in pediatric cystic fibrosis patients." | 9.08 | Pharmacokinetic disposition of sequential intravenous/oral ciprofloxacin in pediatric cystic fibrosis patients with acute pulmonary exacerbation. ( Church, DA; Echols, RM; Kuhn, RJ; Lettieri, JT; Miles, MV; Rubio, TT, 1997) |
| "More data on the efficacy and safety of ciprofloxacin in pediatric cystic fibrosis patients are needed." | 9.08 | Oral ciprofloxacin vs. intravenous ceftazidime plus tobramycin in pediatric cystic fibrosis patients: comparison of antipseudomonas efficacy and assessment of safety with ultrasonography and magnetic resonance imaging. Cystic Fibrosis Study Group. ( Hampel, BJ; Nousia-Arvanitakis, S; Richard, DA; Schaad, UB; Sollich, V; Sommerauer, B, 1997) |
| "Ciprofloxacin is effective for treating pulmonary infection in adult cystic fibrosis patients, and demonstrates excellent efficacy against Pseudomonas aeruginosa, but its use in paediatric cystic fibrosis patients has been limited because quinolone-induced cartilage toxicity has been observed in juvenile animals and has been considered a potential risk for children." | 9.08 | Oral ciprofloxacin in the treatment of pseudomonas exacerbations of paediatric cystic fibrosis: clinical efficacy and safety evaluation using magnetic resonance image scanning. ( Daggett, S; Kubin, R; MacFarland, M; Mitchell, M; Redmond, A; Sweeney, L, 1998) |
| "The caffeine breath test was carried out in six children with cystic fibrosis, before and during a course of ciprofloxacin." | 9.07 | Inhibition of caffeine metabolism by ciprofloxacin in children with cystic fibrosis as measured by the caffeine breath test. ( Choonara, I; Heaf, D; Kitteringham, NR; Parker, AC; Preston, T, 1994) |
| "In 31 adult patients with cystic fibrosis (CF) who were chronically infected with Pseudomonas aeruginosa we examined the effect of giving regular three monthly oral ciprofloxacin." | 9.07 | Regular three monthly oral ciprofloxacin in adult cystic fibrosis patients infected with Pseudomonas aeruginosa. ( Assoufi, BK; Hodson, ME; Sheldon, CD, 1993) |
| "Efficacy and safety of oral ciprofloxacin were studied in a prospective study at three cystic fibrosis centres, covering 24 in-patients suffering from cystic fibrosis and acute bronchopulmonary exacerbation." | 9.07 | [Oral ciprofloxacin therapy in juvenile patients with cystic fibrosis--results of a prospective pilot study]. ( Brömme, S; Handrick, W; Kharari, H; Klöditz, E; Patsch, R; Rumler, W; Schuster, R; Sollich, V; Spencker, FB, 1993) |
| "In order to determine the optimal antipseudomonal therapy in patients with cystic fibrosis aztreonam plus amikacin was compared to ceftazidime plus amikacin, and these two-week hospital regimens were followed by oral ciprofloxacin given for four weeks." | 9.06 | Antipseudomonal therapy in cystic fibrosis: aztreonam and amikacin versus ceftazidime and amikacin administered intravenously followed by oral ciprofloxacin. ( Buehlmann, U; Guenin, K; Kraemer, R; Schaad, UB; Wedgwood-Krucko, J, 1989) |
| "In order to evaluate the clinical efficacy and safety of oral ciprofloxacin in the treatment of acute pulmonary exacerbations of cystic fibrosis and trace the possible development of resistance over time, three trials were conducted." | 9.06 | Use of ciprofloxacin in cystic fibrosis patients. ( Bosso, JA, 1989) |
| "The single-dose pharmacokinetics of oral ciprofloxacin were studied in ten patients with cystic fibrosis aged 18 to 34 years." | 9.06 | Single-dose pharmacokinetics of oral ciprofloxacin in patients with cystic fibrosis. ( Diaz, M; Gandhi, R; Goldfarb, J; Goltzman, C; Guideri, G; Inchiosa, MA; Mascia, AV; Wormser, GP, 1986) |
| "The steady state pharmacokinetic properties of ciprofloxacin and ofloxacin were compared in cystic fibrosis patients." | 9.06 | Comparative pharmacokinetics of ciprofloxacin and ofloxacin in cystic fibrosis patients. ( Hvidberg, EF; Jensen, T; Pedersen, SS, 1987) |
| "The clinical efficacy and safety of ciprofloxacin and ofloxacin were compared in a prospective, randomized double blind, placebo combined cross-over study in 26 adult cystic fibrosis patients with chronic broncho-pulmonary Pseudomonas aeruginosa infection." | 9.06 | The efficacy and safety of ciprofloxacin and ofloxacin in chronic Pseudomonas aeruginosa infection in cystic fibrosis. ( Høiby, N; Jensen, T; Koch, C; Nielsen, CH; Pedersen, SS, 1987) |
| "Twenty-nine adult patients with cystic fibrosis received 750 or 1,000 mg of ciprofloxacin orally every 12 hours for two weeks." | 9.06 | Pharmacokinetics of two dosage regimens of ciprofloxacin during a two-week therapeutic trial in patients with cystic fibrosis. ( Chartrand, SA; Greenwood, R; Hilman, BC; Marks, MI; Shalit, I; Stutman, HR, 1987) |
| "Ciprofloxacin has potent in vitro activity against Pseudomonas aeruginosa and Pseudomonas cepacia strains isolated from cystic fibrosis patients." | 9.06 | Ciprofloxacin monotherapy for acute pulmonary exacerbations of cystic fibrosis. ( Blumer, JL; Goldfarb, J; Myers, CM; Reed, MD; Stern, RC; Yamashita, TS, 1987) |
| "Twenty adult patients with cystic fibrosis who were experiencing acute pulmonary exacerbations were enrolled in a randomized, controlled trial comparing oral ciprofloxacin with intravenous tobramycin plus azlocillin." | 9.06 | Ciprofloxacin versus tobramycin plus azlocillin in pulmonary exacerbations in adult patients with cystic fibrosis. ( Black, PG; Bosso, JA; Matsen, JM, 1987) |
| "Twenty-nine adult patients with cystic fibrosis who had chronic bronchopulmonary infection were randomly assigned to receive 750 or 1,000 mg of oral ciprofloxacin every 12 hours for two weeks." | 9.06 | Randomized study of two dosage regimens of ciprofloxacin for treating chronic bronchopulmonary infection in patients with cystic fibrosis. ( Chartrand, SA; Hilman, BC; Marks, MI; Shalit, I; Stutman, HR, 1987) |
| "We studied the pharmacokinetics of ciprofloxacin in 12 adult males with and 12 adult males without cystic fibrosis (CF)." | 9.06 | Pharmacokinetics of ciprofloxacin in cystic fibrosis. ( Davis, RL; Heggen, L; Koup, JR; Smith, AL; Stempel, D; Weber, A; Williams-Warren, J, 1987) |
| "Fluoroquinolone antibiotics, namely ciprofloxacin and levofloxacin, play an important role in treating infection in cystic fibrosis (CF) and ciprofloxacin remains the last widely used and orally available antipseudomonal agent." | 8.02 | Delafloxacin--A novel fluoroquinolone for the treatment of ciprofloxacin-resistant Pseudomonas aeruginosa in patients with cystic fibrosis. ( McCaughan, J; Millar, BC; Moore, JE; Rendall, JC, 2021) |
| " aeruginosa isolated from cystic fibrosis and wound patients, and one laboratory strain was treated singly and with combinations of anti-Pseudomonas phage PEV20 and ciprofloxacin." | 7.91 | Bacteriophage PEV20 and Ciprofloxacin Combination Treatment Enhances Removal of Pseudomonas aeruginosa Biofilm Isolated from Cystic Fibrosis and Wound Patients. ( Chan, HK; Chang, RYK; Das, T; Kutter, E; Manos, J; Morales, S, 2019) |
| "This study aimed to design and characterize an inhalable dry powder of ciprofloxacin or levofloxacin combined with the mucolytics acetylcysteine and dornase alfa for the management of pulmonary infections in patients with cystic fibrosis." | 7.85 | Dry powders for the inhalation of ciprofloxacin or levofloxacin combined with a mucolytic agent for cystic fibrosis patients. ( Akdag Cayli, Y; Balducci, AG; Buttini, F; Montanari, S; Oner, L; Sahin, S; Vural, I, 2017) |
| " DoE was employed for optimization of ciprofloxacin loaded PLGA NPs for pulmonary delivery against Pseudomonas aeruginosa infections in cystic fibrosis (CF) lungs." | 7.83 | Optimization of ciprofloxacin complex loaded PLGA nanoparticles for pulmonary treatment of cystic fibrosis infections: Design of experiments approach. ( Günday Türeli, N; Schneider, M; Türeli, AE, 2016) |
| "This paper reports a new, easy, cheap, and fast MEPS-HPLC-PDA method for the simultaneous analysis of ciprofloxacin and levofloxacin, two fluoroquinolones (FLQs) commonly used for the treatment of pulmonary infections in cystic fibrosis (CF) patients." | 7.81 | Determination of ciprofloxacin and levofloxacin in human sputum collected from cystic fibrosis patients using microextraction by packed sorbent-high performance liquid chromatography photodiode array detector. ( Celia, C; Ciavarella, MT; Di Bonaventura, G; Di Marzio, L; Fiscarelli, E; Grande, R; Locatelli, M; Paolino, D; Pompilio, A; Ricciotti, G; Zengin, G, 2015) |
| "The incidence of phototoxicity as a side effect of ciprofloxacin appears to be increased in patients with cystic fibrosis compared to the general population (approximately 2." | 7.78 | Ciprofloxacin-induced phototoxicity in an adult cystic fibrosis population. ( Boyle, J; Elborn, JS; Hall, V; McKenna, KE; Murphy, BP; Tolland, JP, 2012) |
| " Recognizing the thick and tenacious airway mucus seen in the cystic fibrosis (CF) patients as a critical barrier to effective drug delivery, both into the mucus layer itself as well as across that layer to the underlying airway epithelium, we hypothesize that mannitol or NaCl can form inhalable drug carriers, improve drug penetration into the mucus, and ultimately enhance the drug's therapeutic effect." | 7.77 | Mannitol-guided delivery of Ciprofloxacin in artificial cystic fibrosis mucus model. ( Lin, Q; Shin, S; Tsifansky, MD; Yang, Y; Yeo, Y, 2011) |
| "To assess the probability of achieving ciprofloxacin pharmacodynamic targets with currently recommended dosages in order to investigate the risk of ciprofloxacin underexposure in children with cystic fibrosis." | 7.76 | Suboptimal ciprofloxacin dosing as a potential cause of decreased Pseudomonas aeruginosa susceptibility in children with cystic fibrosis. ( Chhun, S; Ferroni, A; Guillot, E; Jullien, V; Pons, G; Sermet, I; Zahar, JR, 2010) |
| "We report two cases of prolonged blood clotting times as demonstrated by a raised international normalised ratio and elevated activated partial thromboplastin time in patients with cystic fibrosis taking ciprofloxacin." | 7.74 | Coagulopathy in two patients with cystic fibrosis treated with ciprofloxacin. ( Jones, AM; Moore, GC; Redfern, J; Shiach, CR; Webb, K, 2007) |
| "Methicillin-resistant Staphylococcus aureus (MRSA) is an increasing problem for patients with cystic fibrosis (CF)." | 7.73 | Risk factors for acquisition of methicillin-resistant Staphylococcus aureus (MRSA) by patients with cystic fibrosis. ( Conway, SP; Denton, M; Nadesalingam, K, 2005) |
| " We report an 18-year-old young woman with cystic fibrosis who experienced a pronounced decline in renal function after oral treatment with ciprofloxacin for 3 weeks." | 7.71 | Ciprofloxacin-induced acute renal failure in a patient with cystic fibrosis. ( Bald, M; Nikolaizik, W; Ratjen, F; Wingen, AM, 2001) |
| "We evaluated the activities of meropenem, imipenem, temocillin, piperacillin, and ceftazidime by determination of the MICs for 66 genotypically characterized Burkholderia cepacia isolates obtained from the sputum of cystic fibrosis patients." | 7.70 | Comparative in vitro activities of meropenem, imipenem, temocillin, piperacillin, and ceftazidime in combination with tobramycin, rifampin, or ciprofloxacin against Burkholderia cepacia isolates from patients with cystic fibrosis. ( Bingen, E; Bonacorsi, S; Fitoussi, F; Lhopital, S, 1999) |
| "To report a case of possible ciprofloxacin-induced arthropathy in an adult patient with cystic fibrosis (CF)." | 7.68 | Arthropathy secondary to ciprofloxacin in an adult cystic fibrosis patient. ( Pleasants, RA; Samuelson, WM; Whitaker, MS, 1993) |
| "The mechanisms of persistence to ciprofloxacin in nine sets of Pseudomonas aeruginosa strains isolated during ciprofloxacin therapy of chronic lung infections in cystic fibrosis patients were studied." | 7.68 | Persistence mechanisms in Pseudomonas aeruginosa from cystic fibrosis patients undergoing ciprofloxacin therapy. ( Bryan, LE; Diver, JM; Rabin, HR; Schollaardt, T; Thorson, C, 1991) |
| "To determine the incidence of resistance to ciprofloxacin in respiratory pathogens isolated from patients with cystic fibrosis (CF) compared with that of isolates from patients without CF." | 7.68 | Resistance to ciprofloxacin of respiratory pathogens in patients with cystic fibrosis. ( Dostal, RE; Seale, JP; Yan, BJ, 1992) |
| "Five serial exposures of mucoid Pseudomonas aeruginosa from patients with cystic fibrosis to subinhibitory concentrations of ciprofloxacin resulted in stepwise increases in the MIC, with a mean proportional increase of 10." | 7.68 | Development of resistance to ciprofloxacin in nutrient-rich and nutrient-limited growth conditions in vitro by Pseudomonas aeruginosa isolates from patients with cystic fibrosis. ( Collier, PS; Ferguson, MI; Scott, EM, 1991) |
| "The effect of pancreatic enzyme supplementation on the absorption of an oral dose of 250 mg of ciprofloxacin was studied in six patients with cystic fibrosis in a crossover design." | 7.68 | Effects of enzyme supplementation on oral absorption of ciprofloxacin in patients with cystic fibrosis. ( Buchanan, N; Cooper, PJ; Mack, G, 1991) |
| "The in vitro activities of two-drug combinations of aztreonam, ciprofloxacin, and ceftazidime were studied in 96 clinical isolates of Pseudomonas aeruginosa and in 20 clinical isolates of Pseudomonas cepacia from cystic fibrosis patients." | 7.68 | In vitro activities of combinations of aztreonam, ciprofloxacin, and ceftazidime against clinical isolates of Pseudomonas aeruginosa and Pseudomonas cepacia from patients with cystic fibrosis. ( Bosso, JA; Matsen, JM; Saxon, BA, 1990) |
| "Thirteen patients with cystic fibrosis and 12 healthy control volunteers received a single oral 800 mg dose of fleroxacin and 800 mg every day for 5 days." | 7.68 | Altered disposition of fleroxacin in patients with cystic fibrosis. ( LeBel, M; Mimeault, J; Ruel, M; Seelmann, R; Sörgel, F; Vallée, F, 1990) |
| "The mechanism of persistence was characterized in Pseudomonas aeruginosa isolates obtained ten days before (4405), on the tenth day of (4419), and four days after (4478) ciprofloxacin therapy in a cystic fibrosis patient." | 7.68 | Persistence of Pseudomonas aeruginosa during ciprofloxacin therapy of a cystic fibrosis patient: transient resistance to quinolones and protein F-deficiency. ( Bryan, LE; Chamberland, S; Malouin, F; Parr, TR; Rabin, HR; Schollaardt, T, 1990) |
| "We evaluated fleroxacin, a newer fluoroquinolone, against isolates from sputum from patients with cystic fibrosis." | 7.68 | Comparative in vitro activity of a new quinolone, fleroxacin, against respiratory pathogens from patients with cystic fibrosis. ( Akaniro, JC; Marks, MI; Stutman, HR; Vidaurre, CE, 1990) |
| " We report the development of benign intracranial hypertension after the use of ciprofloxacin in a teenager with cystic fibrosis." | 7.68 | Benign intracranial hypertension after ciprofloxacin administration. ( Supramaniam, G; Winrow, AP, 1990) |
| "Twelve cystic fibrosis patients, aged over 18, who had developed an acute respiratory exacerbation and who had Pseudomonas species isolated from their sputum, were entered into a clinical trial involving ciprofloxacin." | 7.67 | Clinical and pharmacokinetic aspects of ciprofloxacin in the treatment of acute exacerbations of pseudomonas infection in cystic fibrosis patients. ( Black, AE; Collier, PS; Redmond, AO; Scott, EM; Steen, HJ; Stevenson, MI, 1989) |
| "Twenty patients (17-27 yr) with cystic fibrosis were given ciprofloxacin at 30 pulmonary infectious exacerbations." | 7.67 | Comparison of efficacy and tolerance of intravenously and orally administered ciprofloxacin in cystic fibrosis patients with acute exacerbations of lung infection. ( Hjelte, L; Lindblad, A; Ljungberg, B; Malmborg, AS; Nilsson-Ehle, I; Strandvik, B, 1989) |
| "The pharmacokinetics and blister fluid penetration of oral ciprofloxacin were compared in 11 cystic fibrosis (CF) patients who had sputum colonization but were asymptomatic and in 12 healthy volunteers after a single dose (500 mg) and at steady state (500 mg every 8 h)." | 7.67 | Pharmacokinetics and pharmacodynamics of ciprofloxacin in cystic fibrosis patients. ( Bergeron, MG; Bigonesse, P; Chassé, G; Fiset, C; LeBel, M; Rivard, G; Vallée, F, 1986) |
| "Ten patients with cystic fibrosis received 19 therapeutic courses of ciprofloxacin at a dose of 750 mg orally twice daily." | 7.67 | Ciprofloxacin in the treatment of Pseudomonas infection in cystic fibrosis patients. ( Rubio, TT; Shapiro, C, 1986) |
| "An in-vitro pharmacokinetic model was used to simulate ciprofloxacin concentrations in serum observed in vivo following oral doses of 250, 500 and 750 mg, in a culture of Pseudomonas aeruginosa isolated from the sputum of a cystic fibrosis patient." | 7.67 | Effect of ciprofloxacin in an in-vitro pharmacokinetic model against Pseudomonas aeruginosa isolated during cystic fibrosis lung infection. ( Collier, PS; Scott, EM; Stevenson, MI, 1988) |
| "The single-dose pharmacokinetics of oral ciprofloxacin 750 mg were evaluated in six subjects with cystic fibrosis (CF subjects) and six age, sex and approximate weight-matched control subjects (controls)." | 7.67 | Lack of unique ciprofloxacin pharmacokinetic characteristics in patients with cystic fibrosis. ( Blumer, JL; Myers, CM; Reed, MD; Stern, RC; Yamashita, TS, 1988) |
| "The use of ciprofloxacin for the treatment of pulmonary infection in cystic fibrosis patients was investigated." | 7.67 | The use of ciprofloxacin in the treatment of patients with cystic fibrosis. ( Bakker, W; Mattie, H; van den Broek, PJ; van Gulpen, C, 1987) |
| "Levels of ciprofloxacin in serum and sputum were studied for eight patients with cystic fibrosis who were infected with Pseudomonas aeruginosa." | 7.67 | Pharmacokinetics and sputum penetration of ciprofloxacin in patients with cystic fibrosis. ( Batten, JC; Bowyer, H; Hodson, ME; Smith, MJ; White, LO; Willis, J, 1986) |
| "5 mg or 65 mg was well tolerated with similar incidences of adverse events across all groups." | 6.80 | Safety and pharmacokinetics of ciprofloxacin dry powder for inhalation in cystic fibrosis: a phase I, randomized, single-dose, dose-escalation study. ( Delesen, H; Nagelschmitz, J; Staab, D; Stass, H, 2015) |
| "Ciprofloxacin DPI was absorbed rapidly after inhalation." | 6.78 | Tolerability and pharmacokinetic properties of ciprofloxacin dry powder for inhalation in patients with cystic fibrosis: a phase I, randomized, dose-escalation study. ( Nagelschmitz, J; Rolinck-Werninghaus, C; Staab, D; Stass, H; Weimann, B, 2013) |
| " The purpose of this prospective study was to (i) develop a pharmacokinetic (PK) model to be utilized for therapeutic drug monitoring (TDM) of ciprofloxacin and (ii) evaluate current ciprofloxacin dosing regimens for pneumonias in cystic fibrosis (CF) patients." | 6.70 | Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis. ( Aminimanizani, A; Beringer, PM; Gill, MA; Jelliffe, R; Louie, SG; Montgomery, MJ; Shapiro, BJ, 2001) |
| "Oral ciprofloxacin is a useful short-term treatment for patients with CF who are infected with Ps aeruginosa." | 6.66 | Oral ciprofloxacin compared with conventional intravenous treatment for Pseudomonas aeruginosa infection in adults with cystic fibrosis. ( Batten, JC; Butland, RJ; Hodson, ME; Roberts, CM; Smith, MJ, 1987) |
| "Ciprofloxacin is a major advance in the treatment of bronchopulmonary infection in patients with cystic fibrosis." | 6.66 | Ciprofloxacin therapy in cystic fibrosis. ( Davidson, S; Nakatomi, M; Neu, HC; Ores, C; Scully, BE, 1987) |
| "The sputum pharmacokinetics and clinical efficacy of ciprofloxacin in lower respiratory tract infections is reviewed." | 6.16 | Clinical efficacy of ciprofloxacin in lower respiratory tract infections. ( Pedersen, SS, 1989) |
| "Nebulized gentamicin solution combined with systemic antibiotics appears to be safe and has comparable efficacy to other strategies in eradicating early Pa infections in children with CF." | 5.51 | Nebulized gentamicin in combination with systemic antibiotics for eradicating early Pseudomonas aeruginosa infection in children with cystic fibrosis. ( Morrow, BM; Van Stormbroek, B; Zampoli, M, 2019) |
| " Methods An open-label, prospective pharmacokinetic study was performed." | 5.46 | Individual pharmacokinetic variation leads to underdosing of ciprofloxacin in some cystic fibrosis patients. ( Buchard, A; Dalbøge, CS; Dalhoff, K; Duno, M; Høiby, N; Johansen, HK; Nielsen, XC; Pressler, T; Schultz, AN; Wang, H, 2017) |
| " The bactericidal activity of CSA-13 in combination with colistin was measured using the time-kill curve method for two strains." | 5.37 | In vitro activities of the novel ceragenin CSA-13, alone or in combination with colistin, tobramycin, and ciprofloxacin, against Pseudomonas aeruginosa strains isolated from cystic fibrosis patients. ( Bozkurt-Guzel, C; Gerceker, AA; Savage, PB, 2011) |
| "Levofloxacin was the most potent antibiotic against all cystic fibrosis isolates tested, with MIC(90)s ranging from 8 to 32 microg/ml." | 5.36 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. ( Burns, JL; Dudley, MN; Griffith, DC; King, P; Lomovskaya, O, 2010) |
| "Acute renal insufficiency is known to occur in patients who are taking ciprofloxacin, particularly the elderly." | 5.32 | Ciprofloxacin-induced renal insufficiency in cystic fibrosis. ( Moffett, BS; Mogayzel, PJ; Rosenstein, BJ, 2003) |
| "Ciprofloxacin has been a major advance in the treatment of chronic respiratory infections." | 5.29 | Long-term persistence of ciprofloxacin-resistant Haemophilus influenzae in patients with cystic fibrosis. ( Baquero, F; Campos, J; Cantón, R; Escobar, H; García, C; Georgiou, M; Gómez-Lus, R; Román, F, 1996) |
| "Ciprofloxacin was administered orally (15 mg/kg of body weight) or intravenously (6 mg/kg) twice a day for at least 10 days during separate treatment periods." | 5.28 | Increased oral bioavailability of ciprofloxacin in cystic fibrosis patients. ( Christensson, BA; Hjelte, L; Lindblad, A; Ljungberg, B; Malmborg, AS; Nilsson-Ehle, I; Strandvik, B, 1992) |
| "Ciprofloxacin is a potentially useful agent for the treatment of acute pseudomonal pulmonary exacerbations in children with cystic fibrosis." | 5.27 | In-vitro activity of ciprofloxacin and other antibacterial agents against Pseudomonas aeruginosa and Pseudomonas cepacia from cystic fibrosis patients. ( Aronoff, SC; Klinger, JD, 1985) |
| "Ciprofloxacin is a fluorinated carboxyquinolone that inhibits Enterobacteriaceae, staphylococci, and Pseudomonas at low concentrations." | 5.27 | Effect of ciprofloxacin on fecal flora of patients with cystic fibrosis and other patients treated with oral ciprofloxacin. ( Chin, NX; Jules, K; Neu, HC; Scully, BE, 1987) |
| "The pharmacokinetic characteristics of ciprofloxacin were studied in 10 children with cystic fibrosis, aged from 6 to 16 years, who had completed the standard regimen of intravenous ceftazidime and amikacin." | 5.08 | Pharmacokinetics of ciprofloxacin in pediatric cystic fibrosis patients. ( Fischer, C; Hampel, B; Kuhlmann, J; Schaad, UB; Schaefer, HG; Stass, H; Wedgwood, J, 1996) |
| "/oral ciprofloxacin monotherapy offers a safe and efficacious alternative to standard parenteral therapy for acute pulmonary exacerbations in pediatric cystic fibrosis patients." | 5.08 | Sequential ciprofloxacin therapy in pediatric cystic fibrosis: comparative study vs. ceftazidime/tobramycin in the treatment of acute pulmonary exacerbations. The Cystic Fibrosis Study Group. ( Church, DA; Echols, RM; Haverstock, DC; Kanga, JF; Kuhn, RJ; Painter, BG; Perroncel, RY; Rubio, TT; Spohn, WA; Stevens, JC; Thurberg, BE, 1997) |
| "The efficacy and safety of oral ciprofloxacin as a maintenance antipseudomonal therapy were evaluated in 44 patients with cystic fibrosis who had completed a 14-day regimen of intensive hospital therapy with intravenous ceftazidime and amikacin, supplemented by amikacin inhalation therapy." | 5.08 | Ciprofloxacin as antipseudomonal treatment in patients with cystic fibrosis. ( Hampel, B; Kraemer, R; Ruedeberg, A; Schaad, UB; Wedgwood, J, 1997) |
| " This study examined the disposition of sequentially administered intravenous and oral ciprofloxacin, as well as provided dosing recommendations, for the treatment of acute pulmonary exacerbations in pediatric cystic fibrosis patients." | 5.08 | Pharmacokinetic disposition of sequential intravenous/oral ciprofloxacin in pediatric cystic fibrosis patients with acute pulmonary exacerbation. ( Church, DA; Echols, RM; Kuhn, RJ; Lettieri, JT; Miles, MV; Rubio, TT, 1997) |
| "More data on the efficacy and safety of ciprofloxacin in pediatric cystic fibrosis patients are needed." | 5.08 | Oral ciprofloxacin vs. intravenous ceftazidime plus tobramycin in pediatric cystic fibrosis patients: comparison of antipseudomonas efficacy and assessment of safety with ultrasonography and magnetic resonance imaging. Cystic Fibrosis Study Group. ( Hampel, BJ; Nousia-Arvanitakis, S; Richard, DA; Schaad, UB; Sollich, V; Sommerauer, B, 1997) |
| "Ciprofloxacin is effective for treating pulmonary infection in adult cystic fibrosis patients, and demonstrates excellent efficacy against Pseudomonas aeruginosa, but its use in paediatric cystic fibrosis patients has been limited because quinolone-induced cartilage toxicity has been observed in juvenile animals and has been considered a potential risk for children." | 5.08 | Oral ciprofloxacin in the treatment of pseudomonas exacerbations of paediatric cystic fibrosis: clinical efficacy and safety evaluation using magnetic resonance image scanning. ( Daggett, S; Kubin, R; MacFarland, M; Mitchell, M; Redmond, A; Sweeney, L, 1998) |
| "The caffeine breath test was carried out in six children with cystic fibrosis, before and during a course of ciprofloxacin." | 5.07 | Inhibition of caffeine metabolism by ciprofloxacin in children with cystic fibrosis as measured by the caffeine breath test. ( Choonara, I; Heaf, D; Kitteringham, NR; Parker, AC; Preston, T, 1994) |
| "In 31 adult patients with cystic fibrosis (CF) who were chronically infected with Pseudomonas aeruginosa we examined the effect of giving regular three monthly oral ciprofloxacin." | 5.07 | Regular three monthly oral ciprofloxacin in adult cystic fibrosis patients infected with Pseudomonas aeruginosa. ( Assoufi, BK; Hodson, ME; Sheldon, CD, 1993) |
| "Efficacy and safety of oral ciprofloxacin were studied in a prospective study at three cystic fibrosis centres, covering 24 in-patients suffering from cystic fibrosis and acute bronchopulmonary exacerbation." | 5.07 | [Oral ciprofloxacin therapy in juvenile patients with cystic fibrosis--results of a prospective pilot study]. ( Brömme, S; Handrick, W; Kharari, H; Klöditz, E; Patsch, R; Rumler, W; Schuster, R; Sollich, V; Spencker, FB, 1993) |
| "To assess whether chronic pulmonary colonisation with Pseudomonas aeruginosa in cystic fibrosis is preventable, 26 patients who had never received anti-pseudomonas chemotherapy were randomly allocated to groups receiving either no anti-pseudomonas chemotherapy or oral ciprofloxacin and aerosol inhalations of colistin twice daily for 3 weeks, whenever Ps aeruginosa was isolated from routine sputum cultures." | 5.07 | Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment. ( Høiby, N; Koch, C; Valerius, NH, 1991) |
| "In order to determine the optimal antipseudomonal therapy in patients with cystic fibrosis aztreonam plus amikacin was compared to ceftazidime plus amikacin, and these two-week hospital regimens were followed by oral ciprofloxacin given for four weeks." | 5.06 | Antipseudomonal therapy in cystic fibrosis: aztreonam and amikacin versus ceftazidime and amikacin administered intravenously followed by oral ciprofloxacin. ( Buehlmann, U; Guenin, K; Kraemer, R; Schaad, UB; Wedgwood-Krucko, J, 1989) |
| "In order to evaluate the clinical efficacy and safety of oral ciprofloxacin in the treatment of acute pulmonary exacerbations of cystic fibrosis and trace the possible development of resistance over time, three trials were conducted." | 5.06 | Use of ciprofloxacin in cystic fibrosis patients. ( Bosso, JA, 1989) |
| "The single-dose pharmacokinetics of oral ciprofloxacin were studied in ten patients with cystic fibrosis aged 18 to 34 years." | 5.06 | Single-dose pharmacokinetics of oral ciprofloxacin in patients with cystic fibrosis. ( Diaz, M; Gandhi, R; Goldfarb, J; Goltzman, C; Guideri, G; Inchiosa, MA; Mascia, AV; Wormser, GP, 1986) |
| "The steady state pharmacokinetic properties of ciprofloxacin and ofloxacin were compared in cystic fibrosis patients." | 5.06 | Comparative pharmacokinetics of ciprofloxacin and ofloxacin in cystic fibrosis patients. ( Hvidberg, EF; Jensen, T; Pedersen, SS, 1987) |
| "The clinical efficacy and safety of ciprofloxacin and ofloxacin were compared in a prospective, randomized double blind, placebo combined cross-over study in 26 adult cystic fibrosis patients with chronic broncho-pulmonary Pseudomonas aeruginosa infection." | 5.06 | The efficacy and safety of ciprofloxacin and ofloxacin in chronic Pseudomonas aeruginosa infection in cystic fibrosis. ( Høiby, N; Jensen, T; Koch, C; Nielsen, CH; Pedersen, SS, 1987) |
| "Twenty-nine adult patients with cystic fibrosis received 750 or 1,000 mg of ciprofloxacin orally every 12 hours for two weeks." | 5.06 | Pharmacokinetics of two dosage regimens of ciprofloxacin during a two-week therapeutic trial in patients with cystic fibrosis. ( Chartrand, SA; Greenwood, R; Hilman, BC; Marks, MI; Shalit, I; Stutman, HR, 1987) |
| "Ciprofloxacin has potent in vitro activity against Pseudomonas aeruginosa and Pseudomonas cepacia strains isolated from cystic fibrosis patients." | 5.06 | Ciprofloxacin monotherapy for acute pulmonary exacerbations of cystic fibrosis. ( Blumer, JL; Goldfarb, J; Myers, CM; Reed, MD; Stern, RC; Yamashita, TS, 1987) |
| "Twenty adult patients with cystic fibrosis who were experiencing acute pulmonary exacerbations were enrolled in a randomized, controlled trial comparing oral ciprofloxacin with intravenous tobramycin plus azlocillin." | 5.06 | Ciprofloxacin versus tobramycin plus azlocillin in pulmonary exacerbations in adult patients with cystic fibrosis. ( Black, PG; Bosso, JA; Matsen, JM, 1987) |
| "Twenty-nine adult patients with cystic fibrosis who had chronic bronchopulmonary infection were randomly assigned to receive 750 or 1,000 mg of oral ciprofloxacin every 12 hours for two weeks." | 5.06 | Randomized study of two dosage regimens of ciprofloxacin for treating chronic bronchopulmonary infection in patients with cystic fibrosis. ( Chartrand, SA; Hilman, BC; Marks, MI; Shalit, I; Stutman, HR, 1987) |
| "We studied the pharmacokinetics of ciprofloxacin in 12 adult males with and 12 adult males without cystic fibrosis (CF)." | 5.06 | Pharmacokinetics of ciprofloxacin in cystic fibrosis. ( Davis, RL; Heggen, L; Koup, JR; Smith, AL; Stempel, D; Weber, A; Williams-Warren, J, 1987) |
| "This brief review will clarify the association of quinolones with arthropathy, particularly ciprofloxacin because of its widespread use, and subsequently discuss the problem of defining that association in a population of children with cystic fibrosis." | 4.79 | Rheumatologic aspects of pediatric cystic fibrosis patients treated with fluoroquinolones. ( Warren, RW, 1997) |
| " Previous data in 634 adolescents and children treated with compassionate use ciprofloxacin demonstrated low rates of reversible arthralgia and a safety profile similar to that for adult patients." | 4.79 | Ciprofloxacin in pediatrics: worldwide clinical experience based on compassionate use--safety report. ( Hampel, B; Hullmann, R; Schmidt, H, 1997) |
| " In cystic fibrosis-associated acute exacerbations of chronic pseudomonal pneumonitis, the outcome of oral ciprofloxacin therapy was very satisfactory in the six major studies reported (approximately 85% improvement rates)." | 4.77 | Clinical utility of new quinolones in treatment of osteomyelitis and lower respiratory tract infections. ( Bayer, AS, 1989) |
| " aeruginosa strains were isolated from cystic fibrosis patients and minimum inhibitory concentration of amikacin, tobramycin, and ciprofloxacin was determined against all the strains." | 4.31 | Determining effects of nitrate, arginine, and ferrous on antibiotic recalcitrance of clinical strains of Pseudomonas aeruginosa in biofilm-inspired alginate encapsulates. ( Beigverdi, R; Emaneini, M; Halimi, S; Jabalameli, F; Siroosi, M, 2023) |
| " Concomitantly, high entrapment or encapsulation efficiencies (%EE) were achieved, as illustrated in this work for β-carotene and vitamins derivatives (>85%) for cosmetic application, and for antibiotics currently used in chemotherapy, like rifampicin (69-85%) and pyrazinamide (14-29%) against Mycobacterium tuberculosis (TB), and ciprofloxacin (>65%) and tobramycin (~100%) in Cystic Fibrosis (CF) respiratory infections therapy." | 4.12 | LipNanoCar Technology - A Versatile and Scalable Technology for the Production of Lipid Nanoparticles. ( de Barros, DPC; Dos Santos, ACA; Esgueira, VLR; Fonseca, LP; Leitão, JH; Lopes, CPA; Pinto, F; Sousa, SA, 2022) |
| " Additionally, multiple drug hypersensitivity in five patients (distant n = 4, sequential n = 1), among whom two patients showed hypersensitivity against ceftazidime/piperacillin-tazobactam+ ciprofloxacin/levofloxacin, two patients showed hypersensitivity against ceftazidime+ ciprofloxacin n = 2, and one patient showed hypersensitivity against piperacillin-tazobactam+ amikacin+ trimethoprim-sulfamethoxazole." | 4.12 | Antibiotic allergy in children with cystic fibrosis: A retrospective case-control study. ( Güler, N; Süleyman, A; Tamay, Z, 2022) |
| "Fluoroquinolone antibiotics, namely ciprofloxacin and levofloxacin, play an important role in treating infection in cystic fibrosis (CF) and ciprofloxacin remains the last widely used and orally available antipseudomonal agent." | 4.02 | Delafloxacin--A novel fluoroquinolone for the treatment of ciprofloxacin-resistant Pseudomonas aeruginosa in patients with cystic fibrosis. ( McCaughan, J; Millar, BC; Moore, JE; Rendall, JC, 2021) |
| " aeruginosa isolated from cystic fibrosis and wound patients, and one laboratory strain was treated singly and with combinations of anti-Pseudomonas phage PEV20 and ciprofloxacin." | 3.91 | Bacteriophage PEV20 and Ciprofloxacin Combination Treatment Enhances Removal of Pseudomonas aeruginosa Biofilm Isolated from Cystic Fibrosis and Wound Patients. ( Chan, HK; Chang, RYK; Das, T; Kutter, E; Manos, J; Morales, S, 2019) |
| "Ciprofloxacin (CFX) is a fluoroquinolone antibiotic used as a first line treatment against infections caused by Pseudomonas aeruginosa and Streptococcus pneumonia that are commonly acquired by cystic fibrosis (CF) patients." | 3.88 | Fabrication of inhaled hybrid silver/ciprofloxacin nanoparticles with synergetic effect against Pseudomonas aeruginosa. ( Al-Obaidi, H; Kalgudi, R; Zariwala, MG, 2018) |
| "This study aimed to design and characterize an inhalable dry powder of ciprofloxacin or levofloxacin combined with the mucolytics acetylcysteine and dornase alfa for the management of pulmonary infections in patients with cystic fibrosis." | 3.85 | Dry powders for the inhalation of ciprofloxacin or levofloxacin combined with a mucolytic agent for cystic fibrosis patients. ( Akdag Cayli, Y; Balducci, AG; Buttini, F; Montanari, S; Oner, L; Sahin, S; Vural, I, 2017) |
| "Sodium nitrite inhibits bacterial respiration and is in development as an antimicrobial for chronic bacterial infections associated with cystic fibrosis." | 3.85 | Sodium Nitrite Inhibits Killing of Pseudomonas aeruginosa Biofilms by Ciprofloxacin. ( Bomberger, JM; Kocak, BR; Zemke, AC, 2017) |
| " DoE was employed for optimization of ciprofloxacin loaded PLGA NPs for pulmonary delivery against Pseudomonas aeruginosa infections in cystic fibrosis (CF) lungs." | 3.83 | Optimization of ciprofloxacin complex loaded PLGA nanoparticles for pulmonary treatment of cystic fibrosis infections: Design of experiments approach. ( Günday Türeli, N; Schneider, M; Türeli, AE, 2016) |
| "This paper reports a new, easy, cheap, and fast MEPS-HPLC-PDA method for the simultaneous analysis of ciprofloxacin and levofloxacin, two fluoroquinolones (FLQs) commonly used for the treatment of pulmonary infections in cystic fibrosis (CF) patients." | 3.81 | Determination of ciprofloxacin and levofloxacin in human sputum collected from cystic fibrosis patients using microextraction by packed sorbent-high performance liquid chromatography photodiode array detector. ( Celia, C; Ciavarella, MT; Di Bonaventura, G; Di Marzio, L; Fiscarelli, E; Grande, R; Locatelli, M; Paolino, D; Pompilio, A; Ricciotti, G; Zengin, G, 2015) |
| "For 3 weeks, we administered oral AB (ciprofloxacin/metronidazole) or control treatment to homozygous ΔF508 (Δ/Δ), cystic fibrosis transmembrane conductance regulator (CFTR) knockout (-/-), and wild-type (WT) mice and quantified fat absorption using a 72-h fat balance test." | 3.78 | Effect of antibiotic treatment on fat absorption in mice with cystic fibrosis. ( Bijvelds, MJ; Burgerhof, JG; de Jonge, HR; De Lisle, RC; Verkade, HJ; Wouthuyzen-Bakker, M, 2012) |
| "The incidence of phototoxicity as a side effect of ciprofloxacin appears to be increased in patients with cystic fibrosis compared to the general population (approximately 2." | 3.78 | Ciprofloxacin-induced phototoxicity in an adult cystic fibrosis population. ( Boyle, J; Elborn, JS; Hall, V; McKenna, KE; Murphy, BP; Tolland, JP, 2012) |
| " Recognizing the thick and tenacious airway mucus seen in the cystic fibrosis (CF) patients as a critical barrier to effective drug delivery, both into the mucus layer itself as well as across that layer to the underlying airway epithelium, we hypothesize that mannitol or NaCl can form inhalable drug carriers, improve drug penetration into the mucus, and ultimately enhance the drug's therapeutic effect." | 3.77 | Mannitol-guided delivery of Ciprofloxacin in artificial cystic fibrosis mucus model. ( Lin, Q; Shin, S; Tsifansky, MD; Yang, Y; Yeo, Y, 2011) |
| " Altered pharmacokinetics of fluoroquinolones have been described in cystic fibrosis patients as for other drugs, and a higher dosage than usual is recommended." | 3.77 | Fluoroquinolones in the treatment of cystic fibrosis: a critical appraisal. ( LeBel, M, 1991) |
| "To assess the probability of achieving ciprofloxacin pharmacodynamic targets with currently recommended dosages in order to investigate the risk of ciprofloxacin underexposure in children with cystic fibrosis." | 3.76 | Suboptimal ciprofloxacin dosing as a potential cause of decreased Pseudomonas aeruginosa susceptibility in children with cystic fibrosis. ( Chhun, S; Ferroni, A; Guillot, E; Jullien, V; Pons, G; Sermet, I; Zahar, JR, 2010) |
| "Retrospective analysis of 189 nonredundant strains of Pseudomonas aeruginosa sequentially recovered from the sputum samples of 46 cystic fibrosis (CF) patients over a 10-year period (1998 to 2007) revealed that 53 out of 189 (28%) samples were hypersusceptible to the beta-lactam antibiotic ticarcillin (MIC < or = 4 microg/ml) (phenotype dubbed Tic(hs))." | 3.75 | Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. ( Attrée, I; Ducruix, A; El Garch, F; Llanes, C; Muller, C; Phan, G; Plésiat, P; Vettoretti, L, 2009) |
| "Thymidine-dependent small-colony variants (TD-SCVs) of Staphylococcus aureus can be isolated from the airway secretions of patients suffering from cystic fibrosis (CF) and are implicated in persistent and treatment-resistant infections." | 3.74 | The thymidine-dependent small-colony-variant phenotype is associated with hypermutability and antibiotic resistance in clinical Staphylococcus aureus isolates. ( Besier, S; Brade, V; Kahl, BC; Kraiczy, P; Wichelhaus, TA; Zander, J, 2008) |
| "We report two cases of prolonged blood clotting times as demonstrated by a raised international normalised ratio and elevated activated partial thromboplastin time in patients with cystic fibrosis taking ciprofloxacin." | 3.74 | Coagulopathy in two patients with cystic fibrosis treated with ciprofloxacin. ( Jones, AM; Moore, GC; Redfern, J; Shiach, CR; Webb, K, 2007) |
| "Methicillin-resistant Staphylococcus aureus (MRSA) is an increasing problem for patients with cystic fibrosis (CF)." | 3.73 | Risk factors for acquisition of methicillin-resistant Staphylococcus aureus (MRSA) by patients with cystic fibrosis. ( Conway, SP; Denton, M; Nadesalingam, K, 2005) |
| "The aim of the present study was to characterize the population pharmacokinetics of ciprofloxacin in patients with and without cystic fibrosis ranging in age from 1 day to 24 years and to propose a limited sampling strategy to estimate individual pharmacokinetic parameters." | 3.72 | Population pharmacokinetics of ciprofloxacin in pediatric and adolescent patients with acute infections. ( Aigrain, Y; Aujard, Y; Bressolle, F; Jacqz-Aigrain, E; Munck, A; Payen, S; Serreau, R, 2003) |
| " We report an 18-year-old young woman with cystic fibrosis who experienced a pronounced decline in renal function after oral treatment with ciprofloxacin for 3 weeks." | 3.71 | Ciprofloxacin-induced acute renal failure in a patient with cystic fibrosis. ( Bald, M; Nikolaizik, W; Ratjen, F; Wingen, AM, 2001) |
| "We evaluated the activities of meropenem, imipenem, temocillin, piperacillin, and ceftazidime by determination of the MICs for 66 genotypically characterized Burkholderia cepacia isolates obtained from the sputum of cystic fibrosis patients." | 3.70 | Comparative in vitro activities of meropenem, imipenem, temocillin, piperacillin, and ceftazidime in combination with tobramycin, rifampin, or ciprofloxacin against Burkholderia cepacia isolates from patients with cystic fibrosis. ( Bingen, E; Bonacorsi, S; Fitoussi, F; Lhopital, S, 1999) |
| "Ciprofloxacin, a quinolone antibiotic, is used to treat a wide variety of infections including Pseudomonas aeruginosa in patients with cystic fibrosis (CF)." | 3.70 | If you can't stand the rash, get out of the kitchen: an unusual adverse reaction to ciprofloxacin. ( Bush, A; Jaffé, A, 1999) |
| " aeruginosa gyrA encompassing the so-called quinolone resistance-determining region from ciprofloxacin-resistant clinical isolates from patients with cystic fibrosis." | 3.69 | Cloning and nucleotide sequence of Pseudomonas aeruginosa DNA gyrase gyrA gene from strain PAO1 and quinolone-resistant clinical isolates. ( Beckthold, B; Bryan, LE; Diver, JM; Kureishi, A; Schollaardt, T, 1994) |
| "To report a case of possible ciprofloxacin-induced arthropathy in an adult patient with cystic fibrosis (CF)." | 3.68 | Arthropathy secondary to ciprofloxacin in an adult cystic fibrosis patient. ( Pleasants, RA; Samuelson, WM; Whitaker, MS, 1993) |
| "The post-antibiotic effects (PAE) of ceftazidime, ciprofloxacin, imipenem, piperacillin and tobramycin were studied for ten strains of Pseudomonas cepacia isolated from patients with cystic fibrosis." | 3.68 | Post-antibiotic effect of ceftazidime, ciprofloxacin, imipenem, piperacillin and tobramycin for Pseudomonas cepacia. ( Dyke, JW; Hay, MB; Kumar, A; Maier, GA, 1992) |
| "The mechanisms of persistence to ciprofloxacin in nine sets of Pseudomonas aeruginosa strains isolated during ciprofloxacin therapy of chronic lung infections in cystic fibrosis patients were studied." | 3.68 | Persistence mechanisms in Pseudomonas aeruginosa from cystic fibrosis patients undergoing ciprofloxacin therapy. ( Bryan, LE; Diver, JM; Rabin, HR; Schollaardt, T; Thorson, C, 1991) |
| "To determine the incidence of resistance to ciprofloxacin in respiratory pathogens isolated from patients with cystic fibrosis (CF) compared with that of isolates from patients without CF." | 3.68 | Resistance to ciprofloxacin of respiratory pathogens in patients with cystic fibrosis. ( Dostal, RE; Seale, JP; Yan, BJ, 1992) |
| "Five serial exposures of mucoid Pseudomonas aeruginosa from patients with cystic fibrosis to subinhibitory concentrations of ciprofloxacin resulted in stepwise increases in the MIC, with a mean proportional increase of 10." | 3.68 | Development of resistance to ciprofloxacin in nutrient-rich and nutrient-limited growth conditions in vitro by Pseudomonas aeruginosa isolates from patients with cystic fibrosis. ( Collier, PS; Ferguson, MI; Scott, EM, 1991) |
| "The effect of pancreatic enzyme supplementation on the absorption of an oral dose of 250 mg of ciprofloxacin was studied in six patients with cystic fibrosis in a crossover design." | 3.68 | Effects of enzyme supplementation on oral absorption of ciprofloxacin in patients with cystic fibrosis. ( Buchanan, N; Cooper, PJ; Mack, G, 1991) |
| "The in vitro activities of two-drug combinations of aztreonam, ciprofloxacin, and ceftazidime were studied in 96 clinical isolates of Pseudomonas aeruginosa and in 20 clinical isolates of Pseudomonas cepacia from cystic fibrosis patients." | 3.68 | In vitro activities of combinations of aztreonam, ciprofloxacin, and ceftazidime against clinical isolates of Pseudomonas aeruginosa and Pseudomonas cepacia from patients with cystic fibrosis. ( Bosso, JA; Matsen, JM; Saxon, BA, 1990) |
| "Thirteen patients with cystic fibrosis and 12 healthy control volunteers received a single oral 800 mg dose of fleroxacin and 800 mg every day for 5 days." | 3.68 | Altered disposition of fleroxacin in patients with cystic fibrosis. ( LeBel, M; Mimeault, J; Ruel, M; Seelmann, R; Sörgel, F; Vallée, F, 1990) |
| "The mechanism of persistence was characterized in Pseudomonas aeruginosa isolates obtained ten days before (4405), on the tenth day of (4419), and four days after (4478) ciprofloxacin therapy in a cystic fibrosis patient." | 3.68 | Persistence of Pseudomonas aeruginosa during ciprofloxacin therapy of a cystic fibrosis patient: transient resistance to quinolones and protein F-deficiency. ( Bryan, LE; Chamberland, S; Malouin, F; Parr, TR; Rabin, HR; Schollaardt, T, 1990) |
| "We evaluated fleroxacin, a newer fluoroquinolone, against isolates from sputum from patients with cystic fibrosis." | 3.68 | Comparative in vitro activity of a new quinolone, fleroxacin, against respiratory pathogens from patients with cystic fibrosis. ( Akaniro, JC; Marks, MI; Stutman, HR; Vidaurre, CE, 1990) |
| " We report the development of benign intracranial hypertension after the use of ciprofloxacin in a teenager with cystic fibrosis." | 3.68 | Benign intracranial hypertension after ciprofloxacin administration. ( Supramaniam, G; Winrow, AP, 1990) |
| "The Cystic Fibrosis Clinic at the Royal Belfast Hospital for Sick Children has treated 31 children with ciprofloxacin, for serious pseudomonas infection in cystic fibrosis, and carefully monitored the safety and acceptability of the drug." | 3.68 | Tolerance and safety of ciprofloxacin in paediatric patients. ( Black, A; Oborska, IT; Redmond, AO; Steen, HJ, 1990) |
| "Twelve cystic fibrosis patients, aged over 18, who had developed an acute respiratory exacerbation and who had Pseudomonas species isolated from their sputum, were entered into a clinical trial involving ciprofloxacin." | 3.67 | Clinical and pharmacokinetic aspects of ciprofloxacin in the treatment of acute exacerbations of pseudomonas infection in cystic fibrosis patients. ( Black, AE; Collier, PS; Redmond, AO; Scott, EM; Steen, HJ; Stevenson, MI, 1989) |
| "Twenty patients (17-27 yr) with cystic fibrosis were given ciprofloxacin at 30 pulmonary infectious exacerbations." | 3.67 | Comparison of efficacy and tolerance of intravenously and orally administered ciprofloxacin in cystic fibrosis patients with acute exacerbations of lung infection. ( Hjelte, L; Lindblad, A; Ljungberg, B; Malmborg, AS; Nilsson-Ehle, I; Strandvik, B, 1989) |
| "Oral quinolones such as ciprofloxacin are promising agents in the treatment of serious bronchopulmonary infections due to susceptible gram-negative micro-organisms such as Haemophilus influenzae, Branhamella catarrhalis, Klebsiella pneumoniae and even Pseudomonas aeruginosa." | 3.67 | Role of fluoroquinolones in lower respiratory tract infections. ( Vellend, H, 1989) |
| "The pharmacokinetics and blister fluid penetration of oral ciprofloxacin were compared in 11 cystic fibrosis (CF) patients who had sputum colonization but were asymptomatic and in 12 healthy volunteers after a single dose (500 mg) and at steady state (500 mg every 8 h)." | 3.67 | Pharmacokinetics and pharmacodynamics of ciprofloxacin in cystic fibrosis patients. ( Bergeron, MG; Bigonesse, P; Chassé, G; Fiset, C; LeBel, M; Rivard, G; Vallée, F, 1986) |
| "Ten patients with cystic fibrosis received 19 therapeutic courses of ciprofloxacin at a dose of 750 mg orally twice daily." | 3.67 | Ciprofloxacin in the treatment of Pseudomonas infection in cystic fibrosis patients. ( Rubio, TT; Shapiro, C, 1986) |
| "An in-vitro pharmacokinetic model was used to simulate ciprofloxacin concentrations in serum observed in vivo following oral doses of 250, 500 and 750 mg, in a culture of Pseudomonas aeruginosa isolated from the sputum of a cystic fibrosis patient." | 3.67 | Effect of ciprofloxacin in an in-vitro pharmacokinetic model against Pseudomonas aeruginosa isolated during cystic fibrosis lung infection. ( Collier, PS; Scott, EM; Stevenson, MI, 1988) |
| "The single-dose pharmacokinetics of oral ciprofloxacin 750 mg were evaluated in six subjects with cystic fibrosis (CF subjects) and six age, sex and approximate weight-matched control subjects (controls)." | 3.67 | Lack of unique ciprofloxacin pharmacokinetic characteristics in patients with cystic fibrosis. ( Blumer, JL; Myers, CM; Reed, MD; Stern, RC; Yamashita, TS, 1988) |
| "The use of ciprofloxacin for the treatment of pulmonary infection in cystic fibrosis patients was investigated." | 3.67 | The use of ciprofloxacin in the treatment of patients with cystic fibrosis. ( Bakker, W; Mattie, H; van den Broek, PJ; van Gulpen, C, 1987) |
| "Levels of ciprofloxacin in serum and sputum were studied for eight patients with cystic fibrosis who were infected with Pseudomonas aeruginosa." | 3.67 | Pharmacokinetics and sputum penetration of ciprofloxacin in patients with cystic fibrosis. ( Batten, JC; Bowyer, H; Hodson, ME; Smith, MJ; White, LO; Willis, J, 1986) |
| "5 mg or 65 mg was well tolerated with similar incidences of adverse events across all groups." | 2.80 | Safety and pharmacokinetics of ciprofloxacin dry powder for inhalation in cystic fibrosis: a phase I, randomized, single-dose, dose-escalation study. ( Delesen, H; Nagelschmitz, J; Staab, D; Stass, H, 2015) |
| "Ciprofloxacin DPI was absorbed rapidly after inhalation." | 2.78 | Tolerability and pharmacokinetic properties of ciprofloxacin dry powder for inhalation in patients with cystic fibrosis: a phase I, randomized, dose-escalation study. ( Nagelschmitz, J; Rolinck-Werninghaus, C; Staab, D; Stass, H; Weimann, B, 2013) |
| " Adverse events were similar across groups." | 2.76 | Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. ( Burns, JL; Chatfield, BA; Froh, DK; Gibson, RL; Hiatt, P; Khan, U; Kronmal, R; Kulich, M; Mayer-Hamblett, N; Orenstein, D; Ramsey, BW; Retsch-Bogart, G; Rosenfeld, M; Spencer, T; Treggiari, MM; Williams, J, 2011) |
| " The purpose of this prospective study was to (i) develop a pharmacokinetic (PK) model to be utilized for therapeutic drug monitoring (TDM) of ciprofloxacin and (ii) evaluate current ciprofloxacin dosing regimens for pneumonias in cystic fibrosis (CF) patients." | 2.70 | Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis. ( Aminimanizani, A; Beringer, PM; Gill, MA; Jelliffe, R; Louie, SG; Montgomery, MJ; Shapiro, BJ, 2001) |
| " As for its tolerability, adverse reactions chiefly associated with affection of the gastrointestinal tract, i." | 2.69 | [The efficacy and safety of ciprofloxacin in treating children with mucoviscidosis]. ( Kapranov, NI; Perederko, LV; Polikarpova, SV; Postnikov, SS; Semykin, SIu, 2000) |
| "Ciprofloxacin was used either alone (exclusively in outpatients) or in combination with the 2nd or 3rd generation cephalosporins or aminoglycosides." | 2.68 | [Use of ciprofloxacin in children with mucoviscidosis]. ( Belousov, IuB; Kapranov, NI; Kashirskaia, NIu; Semykin, SIu, 1997) |
| "Oral ciprofloxacin is a useful short-term treatment for patients with CF who are infected with Ps aeruginosa." | 2.66 | Oral ciprofloxacin compared with conventional intravenous treatment for Pseudomonas aeruginosa infection in adults with cystic fibrosis. ( Batten, JC; Butland, RJ; Hodson, ME; Roberts, CM; Smith, MJ, 1987) |
| "Ciprofloxacin is a major advance in the treatment of bronchopulmonary infection in patients with cystic fibrosis." | 2.66 | Ciprofloxacin therapy in cystic fibrosis. ( Davidson, S; Nakatomi, M; Neu, HC; Ores, C; Scully, BE, 1987) |
| " The drug dosage was 300 mg every 12 hours in 19 patients and 200 mg intravenously every 12 hours in nine patients." | 2.66 | Treatment of serious infections with intravenous ciprofloxacin. ( Neu, HC; Scully, BE, 1987) |
| "To determine whether antibiotic treatment of early Pseudomonas aeruginosa infection in children and adults with cystic fibrosis eradicates the organism, delays the onset of chronic infection, and results in clinical improvement." | 2.55 | Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. ( Langton Hewer, SC; Smyth, AR, 2017) |
| "To determine whether antibiotic treatment of early Pseudomonas aeruginosa infection in children and adults with cystic fibrosis eradicates the organism, delays the onset of chronic infection, and results in clinical improvement." | 2.50 | Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. ( Langton Hewer, SC; Smyth, AR, 2014) |
| " Older literature supports an oral dosing regimen of 40 mg/kg/day divided every 12 hr, up to 2 g/day, and intravenous (IV) ciprofloxacin 30 mg/kg/day divided every 8 hr, maximum 1." | 2.49 | Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: III. fluoroquinolones. ( Ampofo, K; Sherwin, CM; Spigarelli, MG; Stockmann, C; Waters, CD; Young, DC; Zobell, JT, 2013) |
| "To determine whether antibiotic treatment of early Pseudomonas aeruginosa infection in children and adults with CF eradicates the organism, improves clinical and microbiological outcome and is superior to or more cost-effective than other strategies." | 2.45 | Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. ( Langton Hewer, SC; Smyth, AR, 2009) |
| " Although, in patients with CF, the extent of drug absorption varies widely and the rate of absorption is slower, bioavailability is not altered." | 2.40 | Drug disposition in cystic fibrosis. ( Pons, G; Rey, E; Tréluyer, JM, 1998) |
| " Care in selection of patients, attention to optimal duration of therapy and adequate dosage may help to prevent emergence of resistance but combination therapy has not proven effective." | 2.38 | Emergent resistance to ciprofloxacin amongst Pseudomonas aeruginosa and Staphylococcus aureus: clinical significance and therapeutic approaches. ( Ball, P, 1990) |
| "Cystic fibrosis is a severe, autosomal recessive disease that shortens life expectancy." | 1.91 | Novel therapeutic approach for the treatment of cystic fibrosis based on freeze-dried tridrug microparticles to treat cystic fibrosis. ( Kabra, VD; Lahoti, SR, 2023) |
| "Nebulized gentamicin solution combined with systemic antibiotics appears to be safe and has comparable efficacy to other strategies in eradicating early Pa infections in children with CF." | 1.51 | Nebulized gentamicin in combination with systemic antibiotics for eradicating early Pseudomonas aeruginosa infection in children with cystic fibrosis. ( Morrow, BM; Van Stormbroek, B; Zampoli, M, 2019) |
| "Patients with cystic fibrosis are more susceptible than members of the general population to lung infections." | 1.51 | No benefit of longer eradication therapy of Pseudomonas aeruginosa primoinfections in pediatric cystic fibrosis. ( Claude, F; Hafen, GM; Rochat, I, 2019) |
| " aeruginosa eradication since a biofilm minimal inhibitory dosage would be applied." | 1.48 | Unveiling the early events of Pseudomonas aeruginosa adaptation in cystic fibrosis airway environment using a long-term in vitro maintenance. ( Monteiro, R; Pereira, MO; Sousa, AM, 2018) |
| " Methods An open-label, prospective pharmacokinetic study was performed." | 1.46 | Individual pharmacokinetic variation leads to underdosing of ciprofloxacin in some cystic fibrosis patients. ( Buchard, A; Dalbøge, CS; Dalhoff, K; Duno, M; Høiby, N; Johansen, HK; Nielsen, XC; Pressler, T; Schultz, AN; Wang, H, 2017) |
| "Treatment with ciprofloxacin decreased the viability of PAO1 and ΔkatA biofilms but not of gyrA biofilms." | 1.40 | Formation of hydroxyl radicals contributes to the bactericidal activity of ciprofloxacin against Pseudomonas aeruginosa biofilms. ( Bjarnsholt, T; Briales, A; Brochmann, RP; Ciofu, O; Hempel, C; Høiby, N; Jensen, PØ; Kolpen, M; Kragh, KN; Wang, H, 2014) |
| " The bactericidal activity of CSA-13 in combination with colistin was measured using the time-kill curve method for two strains." | 1.37 | In vitro activities of the novel ceragenin CSA-13, alone or in combination with colistin, tobramycin, and ciprofloxacin, against Pseudomonas aeruginosa strains isolated from cystic fibrosis patients. ( Bozkurt-Guzel, C; Gerceker, AA; Savage, PB, 2011) |
| "Levofloxacin was the most potent antibiotic against all cystic fibrosis isolates tested, with MIC(90)s ranging from 8 to 32 microg/ml." | 1.36 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. ( Burns, JL; Dudley, MN; Griffith, DC; King, P; Lomovskaya, O, 2010) |
| "Ciprofloxacin-resistance was found in 4% of isolates." | 1.35 | Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience. ( Hansen, CR; Høiby, N; Pressler, T, 2008) |
| "Treatment with ciprofloxacin and linezolid was started on the basis of the antibiogram findings." | 1.34 | Successful recovery after disseminated infection due to mycobacterium abscessus in a lung transplant patient: subcutaneous nodule as first manifestation--a case report. ( Blanes, M; Morales, P; Pérez-Enguix, D; Ros, JA; Saiz, V; Santos, M, 2007) |
| " Population pharmacokinetic analyses were performed with NONMEN software." | 1.32 | Population pharmacokinetics of ciprofloxacin in pediatric patients. ( Gastonguay, MR; Rajagopalan, P, 2003) |
| "Acute renal insufficiency is known to occur in patients who are taking ciprofloxacin, particularly the elderly." | 1.32 | Ciprofloxacin-induced renal insufficiency in cystic fibrosis. ( Moffett, BS; Mogayzel, PJ; Rosenstein, BJ, 2003) |
| "Ciprofloxacin (CIP) was the least active agent tested (MIC90 4 microg/ml; 86% susceptible)." | 1.31 | Emerging antimicrobial resistances among Proteus mirabilis in Europe: report from the MYSTIC Program (1997-2001). Meropenem Yearly Susceptibility Test Information Collection. ( Jones, RN; Mutnick, AH; Turner, PJ, 2002) |
| "Nine children were ill with mucoviscidosis and 8 children were ill with aplastic anemia." | 1.31 | [Comparative morphological analysis of the articular cartilage, epiphyseal plate, spongy bone, and synovial membrane of the knee joint in children treated and not treated with ciprofloxacin]. ( Kapranov, NI; Nazhimov, VP; Postnikov, SS; Semykin, SIu, 2000) |
| "Surveillance of ciprofloxacin usage in a pediatric population failed to demonstrate serious or unusually high rates of any adverse events, including joint toxicity." | 1.30 | Ciprofloxacin safety in a pediatric population. ( Jick, S, 1997) |
| "Ciprofloxacin MICs were 0." | 1.30 | In-vitro investigation of the antibacterial activity of agents which may be used for the oral treatment of lung infections in CF patients. ( Hamilton, VE; Richards, RM; Thomas, MR, 1998) |
| "Ciprofloxacin was given at a dose of 200 mg over 30 min by using an automatic pump." | 1.29 | Penetration of ciprofloxacin into bronchial secretions from mechanically ventilated patients with nosocomial bronchopneumonia. ( Bruguerolle, B; De Micco, P; Gouin, F; Mallet, MN; Martin, C; Papazian, L; Saux, P, 1994) |
| "Ciprofloxacin has been a major advance in the treatment of chronic respiratory infections." | 1.29 | Long-term persistence of ciprofloxacin-resistant Haemophilus influenzae in patients with cystic fibrosis. ( Baquero, F; Campos, J; Cantón, R; Escobar, H; García, C; Georgiou, M; Gómez-Lus, R; Román, F, 1996) |
| "Ciprofloxacin was administered orally (15 mg/kg of body weight) or intravenously (6 mg/kg) twice a day for at least 10 days during separate treatment periods." | 1.28 | Increased oral bioavailability of ciprofloxacin in cystic fibrosis patients. ( Christensson, BA; Hjelte, L; Lindblad, A; Ljungberg, B; Malmborg, AS; Nilsson-Ehle, I; Strandvik, B, 1992) |
| "Ciprofloxacin is a potentially useful agent for the treatment of acute pseudomonal pulmonary exacerbations in children with cystic fibrosis." | 1.27 | In-vitro activity of ciprofloxacin and other antibacterial agents against Pseudomonas aeruginosa and Pseudomonas cepacia from cystic fibrosis patients. ( Aronoff, SC; Klinger, JD, 1985) |
| "Ciprofloxacin is a fluorinated carboxyquinolone that inhibits Enterobacteriaceae, staphylococci, and Pseudomonas at low concentrations." | 1.27 | Effect of ciprofloxacin on fecal flora of patients with cystic fibrosis and other patients treated with oral ciprofloxacin. ( Chin, NX; Jules, K; Neu, HC; Scully, BE, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 42 (18.75) | 18.7374 |
| 1990's | 62 (27.68) | 18.2507 |
| 2000's | 43 (19.20) | 29.6817 |
| 2010's | 62 (27.68) | 24.3611 |
| 2020's | 15 (6.70) | 2.80 |
| Authors | Studies |
|---|---|
| Zhou, J | 1 |
| Chen, Y | 1 |
| Tabibi, S | 1 |
| Alba, L | 1 |
| Garber, E | 1 |
| Saiman, L | 2 |
| Besier, S | 1 |
| Zander, J | 1 |
| Kahl, BC | 1 |
| Kraiczy, P | 1 |
| Brade, V | 1 |
| Wichelhaus, TA | 1 |
| Mulet, X | 1 |
| Maciá, MD | 1 |
| Mena, A | 1 |
| Juan, C | 1 |
| Pérez, JL | 1 |
| Oliver, A | 2 |
| Vettoretti, L | 1 |
| Plésiat, P | 1 |
| Muller, C | 1 |
| El Garch, F | 1 |
| Phan, G | 1 |
| Attrée, I | 1 |
| Ducruix, A | 1 |
| Llanes, C | 1 |
| Mandsberg, LF | 1 |
| Ciofu, O | 4 |
| Kirkby, N | 1 |
| Christiansen, LE | 1 |
| Poulsen, HE | 1 |
| Høiby, N | 13 |
| Schurek, KN | 2 |
| Sampaio, JL | 1 |
| Kiffer, CR | 1 |
| Sinto, S | 1 |
| Mendes, CM | 1 |
| Hancock, RE | 2 |
| King, P | 1 |
| Lomovskaya, O | 1 |
| Griffith, DC | 1 |
| Burns, JL | 3 |
| Dudley, MN | 1 |
| Tomás, M | 1 |
| Doumith, M | 1 |
| Warner, M | 2 |
| Turton, JF | 1 |
| Beceiro, A | 1 |
| Bou, G | 1 |
| Livermore, DM | 1 |
| Woodford, N | 1 |
| Alhajj, N | 1 |
| O'Reilly, NJ | 1 |
| Cathcart, H | 1 |
| Sunman, B | 1 |
| Emiralioglu, N | 1 |
| Hazirolan, G | 1 |
| Şener, B | 1 |
| Ozsezen, B | 1 |
| Tural, DA | 1 |
| Buyuksahin, HN | 1 |
| Guzelkas, I | 1 |
| Yalcin, E | 1 |
| Dogru, D | 1 |
| Özçelik, U | 1 |
| Kiper, N | 1 |
| Esgueira, VLR | 1 |
| Lopes, CPA | 1 |
| Dos Santos, ACA | 1 |
| Pinto, F | 1 |
| Sousa, SA | 1 |
| de Barros, DPC | 1 |
| Leitão, JH | 1 |
| Fonseca, LP | 1 |
| Süleyman, A | 1 |
| Tamay, Z | 1 |
| Güler, N | 1 |
| Yilmaz, FN | 3 |
| Hacioglu, M | 3 |
| Aldogan, EH | 3 |
| Law, JP | 3 |
| Wood, AJ | 3 |
| Friman, VP | 3 |
| Kabra, VD | 1 |
| Lahoti, SR | 1 |
| Langton Hewer, SC | 4 |
| Smith, S | 1 |
| Rowbotham, NJ | 1 |
| Yule, A | 1 |
| Smyth, AR | 4 |
| Jabalameli, F | 1 |
| Emaneini, M | 1 |
| Beigverdi, R | 1 |
| Halimi, S | 1 |
| Siroosi, M | 1 |
| Lin, Y | 1 |
| Chang, RYK | 2 |
| Britton, WJ | 1 |
| Morales, S | 2 |
| Kutter, E | 2 |
| Li, J | 1 |
| Chan, HK | 3 |
| Ramsay, KA | 1 |
| Wardell, SJT | 1 |
| Patrick, WM | 1 |
| Brockway, B | 1 |
| Reid, DW | 1 |
| Winstanley, C | 2 |
| Bell, SC | 1 |
| Lamont, IL | 1 |
| Epps, QJ | 1 |
| Epps, KL | 1 |
| Young, DC | 2 |
| Zobell, JT | 2 |
| Lababidi, N | 1 |
| Ofosu Kissi, E | 1 |
| Elgaher, WAM | 1 |
| Sigal, V | 1 |
| Haupenthal, J | 1 |
| Schwarz, BC | 2 |
| Hirsch, AKH | 1 |
| Rades, T | 1 |
| Schneider, M | 5 |
| Millar, BC | 4 |
| Malnarcic, CM | 1 |
| McCaughan, J | 3 |
| Moore, JE | 5 |
| Daboor, SM | 1 |
| Rohde, JR | 1 |
| Cheng, Z | 1 |
| Rendall, JC | 2 |
| Juntke, J | 2 |
| Murgia, X | 1 |
| Günday Türeli, N | 3 |
| Türeli, AE | 3 |
| Thorn, CR | 1 |
| Schneider-Daum, N | 2 |
| de Souza Carvalho-Wodarz, C | 1 |
| Lehr, CM | 2 |
| Monteiro, R | 2 |
| Magalhães, AP | 1 |
| Pereira, MO | 2 |
| Sousa, AM | 2 |
| Akdag Cayli, Y | 1 |
| Sahin, S | 1 |
| Buttini, F | 1 |
| Balducci, AG | 1 |
| Montanari, S | 1 |
| Vural, I | 1 |
| Oner, L | 1 |
| Torge, A | 2 |
| Wagner, S | 1 |
| Chaves, PS | 1 |
| Oliveira, EG | 1 |
| Guterres, SS | 1 |
| Pohlmann, AR | 1 |
| Titz, A | 1 |
| Beck, RCR | 1 |
| Lucca, F | 1 |
| Guarnieri, M | 1 |
| Ros, M | 1 |
| Muffato, G | 1 |
| Rigoli, R | 1 |
| Da Dalt, L | 1 |
| Al-Obaidi, H | 1 |
| Kalgudi, R | 1 |
| Zariwala, MG | 1 |
| Poore, TS | 1 |
| Virella-Lowell, I | 1 |
| Guimbellot, JS | 1 |
| Zaichik, S | 1 |
| Steinbring, C | 1 |
| Menzel, C | 1 |
| Knabl, L | 1 |
| Orth-Höller, D | 1 |
| Ellemunter, H | 1 |
| Niedermayr, K | 1 |
| Bernkop-Schnürch, A | 1 |
| Van Stormbroek, B | 1 |
| Zampoli, M | 1 |
| Morrow, BM | 1 |
| Claude, F | 1 |
| Rochat, I | 1 |
| Hafen, GM | 1 |
| Patel, KK | 1 |
| Tripathi, M | 1 |
| Pandey, N | 1 |
| Agrawal, AK | 1 |
| Gade, S | 1 |
| Anjum, MM | 1 |
| Tilak, R | 1 |
| Singh, S | 1 |
| Das, T | 1 |
| Manos, J | 1 |
| Harun, SN | 1 |
| Holford, NHG | 1 |
| Grimwood, K | 2 |
| Wainwright, CE | 1 |
| Hennig, S | 1 |
| Yang, ZT | 1 |
| Zahar, JR | 2 |
| Méchaï, F | 1 |
| Postaire, M | 1 |
| Blanot, S | 1 |
| Balfagon-Viel, S | 1 |
| Nassif, X | 1 |
| Lortholary, O | 1 |
| Islan, GA | 1 |
| Bosio, VE | 1 |
| Castro, GR | 1 |
| Stass, H | 3 |
| Weimann, B | 1 |
| Nagelschmitz, J | 2 |
| Rolinck-Werninghaus, C | 1 |
| Staab, D | 2 |
| Jensen, PØ | 1 |
| Briales, A | 1 |
| Brochmann, RP | 1 |
| Wang, H | 2 |
| Kragh, KN | 1 |
| Kolpen, M | 1 |
| Hempel, C | 1 |
| Bjarnsholt, T | 1 |
| Delesen, H | 1 |
| Ferreira, AS | 1 |
| Silva, IN | 1 |
| Fernandes, F | 1 |
| Pilkington, R | 1 |
| Callaghan, M | 1 |
| McClean, S | 1 |
| Moreira, LM | 1 |
| Kwan, BW | 1 |
| Chowdhury, N | 1 |
| Wood, TK | 1 |
| Ali, H | 1 |
| Orchard, C | 1 |
| Mariveles, M | 1 |
| Scott, S | 1 |
| Alshafi, K | 1 |
| Bilton, D | 1 |
| Simmonds, N | 1 |
| Connett, GJ | 1 |
| Pike, KC | 1 |
| Legg, JP | 1 |
| Cathie, K | 1 |
| Dewar, A | 1 |
| Foote, K | 1 |
| Harris, A | 1 |
| Faust, SN | 1 |
| Locatelli, M | 1 |
| Ciavarella, MT | 1 |
| Paolino, D | 1 |
| Celia, C | 1 |
| Fiscarelli, E | 1 |
| Ricciotti, G | 1 |
| Pompilio, A | 1 |
| Di Bonaventura, G | 1 |
| Grande, R | 1 |
| Zengin, G | 1 |
| Di Marzio, L | 1 |
| Langan, KM | 1 |
| Kotsimbos, T | 1 |
| Peleg, AY | 1 |
| Furiga, A | 1 |
| Lajoie, B | 1 |
| El Hage, S | 1 |
| Baziard, G | 1 |
| Roques, C | 1 |
| Ang, JY | 1 |
| Abdel-Haq, N | 1 |
| Zhu, F | 1 |
| Thabit, AK | 1 |
| Nicolau, DP | 1 |
| Satlin, MJ | 1 |
| van Duin, D | 1 |
| Zemke, AC | 1 |
| Kocak, BR | 1 |
| Bomberger, JM | 1 |
| Elhissi, A | 1 |
| Schultz, AN | 1 |
| Nielsen, XC | 1 |
| Pressler, T | 4 |
| Dalhoff, K | 1 |
| Duno, M | 1 |
| Buchard, A | 1 |
| Johansen, HK | 2 |
| Dalbøge, CS | 1 |
| Wiegand, I | 1 |
| Marr, AK | 1 |
| Breidenstein, EB | 1 |
| Taylor, P | 1 |
| Hansen, CR | 1 |
| Elborn, JS | 4 |
| Hodson, M | 1 |
| Bertram, C | 1 |
| Braccini, G | 1 |
| Festini, F | 1 |
| Boni, V | 1 |
| Neri, AS | 1 |
| Galici, V | 1 |
| Campana, S | 2 |
| Zavataro, L | 2 |
| Trevisan, F | 2 |
| Braggion, C | 1 |
| Taccetti, G | 2 |
| Treggiari, MM | 3 |
| Rosenfeld, M | 3 |
| Mayer-Hamblett, N | 3 |
| Retsch-Bogart, G | 3 |
| Gibson, RL | 3 |
| Williams, J | 2 |
| Emerson, J | 1 |
| Kronmal, RA | 2 |
| Ramsey, BW | 3 |
| Yang, Y | 2 |
| Tsifansky, MD | 2 |
| Wu, CJ | 1 |
| Yang, HI | 1 |
| Schmidt, G | 1 |
| Yeo, Y | 2 |
| Fothergill, JL | 1 |
| Mowat, E | 1 |
| Ledson, MJ | 1 |
| Walshaw, MJ | 1 |
| Pope, CF | 1 |
| Gillespie, SH | 1 |
| McHugh, TD | 1 |
| Adi, H | 1 |
| Young, PM | 1 |
| Agus, H | 1 |
| Traini, D | 1 |
| García-Castillo, M | 2 |
| del Campo, R | 1 |
| Baquero, F | 4 |
| Morosini, MI | 1 |
| Turrientes, MC | 1 |
| Zamora, J | 1 |
| Cantón, R | 4 |
| Guillot, E | 1 |
| Sermet, I | 1 |
| Ferroni, A | 1 |
| Chhun, S | 1 |
| Pons, G | 2 |
| Jullien, V | 1 |
| Maeda, Y | 1 |
| Murayama, M | 1 |
| Goldsmith, CE | 2 |
| Coulter, WA | 1 |
| Mason, C | 1 |
| Dooley, JS | 1 |
| Lowery, CJ | 1 |
| Matsuda, M | 1 |
| Lillquist, YP | 1 |
| Cho, E | 1 |
| Davidson, AG | 1 |
| García Rodríguez, R | 1 |
| Galindo Bonilla, PA | 1 |
| Feo Brito, FJ | 1 |
| Gómez Torrijos, E | 1 |
| Borja Segade, J | 1 |
| Lara de la Rosa, P | 1 |
| Castro Jiménez, A | 1 |
| Shin, S | 1 |
| Lin, Q | 1 |
| Lisowska, A | 1 |
| Pogorzelski, A | 1 |
| Oracz, G | 1 |
| Skorupa, W | 1 |
| Cofta, S | 1 |
| Szydłowski, J | 1 |
| Socha, J | 1 |
| Walkowiak, J | 1 |
| Khan, U | 2 |
| Cohen, MB | 1 |
| Kulich, M | 1 |
| Kronmal, R | 1 |
| Hiatt, P | 1 |
| Spencer, T | 1 |
| Orenstein, D | 1 |
| Chatfield, BA | 1 |
| Froh, DK | 1 |
| Coban, AY | 1 |
| Tanrıverdi Çaycı, Y | 1 |
| Yıldırım, T | 1 |
| Erturan, Z | 1 |
| Durupınar, B | 1 |
| Bozdoğan, B | 1 |
| Bozkurt-Guzel, C | 1 |
| Savage, PB | 1 |
| Gerceker, AA | 1 |
| Wouthuyzen-Bakker, M | 1 |
| Bijvelds, MJ | 1 |
| de Jonge, HR | 1 |
| De Lisle, RC | 3 |
| Burgerhof, JG | 1 |
| Verkade, HJ | 1 |
| Bianchini, E | 1 |
| Cariani, L | 1 |
| Buzzetti, R | 1 |
| Costantini, D | 1 |
| Serisier, DJ | 1 |
| Hewer, SL | 1 |
| Fernández-Olmos, A | 1 |
| Maiz, L | 1 |
| Lamas, A | 1 |
| Proesmans, M | 1 |
| Vermeulen, F | 1 |
| Boulanger, L | 1 |
| Verhaegen, J | 1 |
| De Boeck, K | 1 |
| Stockmann, C | 1 |
| Sherwin, CM | 1 |
| Waters, CD | 1 |
| Spigarelli, MG | 1 |
| Ampofo, K | 1 |
| Tolland, JP | 1 |
| Murphy, BP | 1 |
| Boyle, J | 1 |
| Hall, V | 1 |
| McKenna, KE | 1 |
| Wong, A | 1 |
| Rodrigue, N | 1 |
| Kassen, R | 1 |
| Mutnick, AH | 1 |
| Turner, PJ | 1 |
| Jones, RN | 1 |
| Manno, G | 1 |
| Ugolotti, E | 1 |
| Belli, ML | 1 |
| Fenu, ML | 1 |
| Romano, L | 1 |
| Cruciani, M | 1 |
| Postnikov, SS | 4 |
| Semykin, SIu | 4 |
| Nazhimov, VP | 3 |
| Novichkova, GA | 1 |
| Rajagopalan, P | 1 |
| Gastonguay, MR | 1 |
| Pitt, TL | 1 |
| Sparrow, M | 1 |
| Stefanidou, M | 1 |
| Payen, S | 1 |
| Serreau, R | 1 |
| Munck, A | 1 |
| Aujard, Y | 1 |
| Aigrain, Y | 1 |
| Bressolle, F | 1 |
| Jacqz-Aigrain, E | 1 |
| Lee, TW | 1 |
| Brownlee, KG | 1 |
| Denton, M | 2 |
| Littlewood, JM | 1 |
| Conway, SP | 2 |
| Ratjen, F | 2 |
| Nørregaard, L | 1 |
| Gøtzsche, PC | 1 |
| Koch, C | 6 |
| Magalhães, M | 1 |
| de Britto, MC | 1 |
| Vandamme, P | 1 |
| Moffett, BS | 1 |
| Rosenstein, BJ | 1 |
| Mogayzel, PJ | 1 |
| Nadesalingam, K | 1 |
| McKnight, AJ | 1 |
| Shaw, A | 1 |
| Clarke, L | 1 |
| Reid, A | 1 |
| Frederiksen, B | 2 |
| Cobos, N | 1 |
| de Gracia, J | 1 |
| Honorato, J | 1 |
| Gartner, S | 1 |
| Alvarez, A | 1 |
| Salcedo, A | 1 |
| García-Quetglas, E | 1 |
| Roveta, S | 1 |
| Schito, AM | 1 |
| Marchese, A | 1 |
| Schito, GC | 1 |
| Roach, EA | 1 |
| Norkina, O | 1 |
| Blau, H | 1 |
| Klein, K | 1 |
| Shalit, I | 3 |
| Halperin, D | 1 |
| Fabian, I | 1 |
| Moore, GC | 1 |
| Redfern, J | 1 |
| Shiach, CR | 1 |
| Webb, K | 1 |
| Jones, AM | 1 |
| Morales, P | 1 |
| Ros, JA | 1 |
| Blanes, M | 1 |
| Pérez-Enguix, D | 1 |
| Saiz, V | 1 |
| Santos, M | 1 |
| Pedersen, SS | 6 |
| Jensen, T | 4 |
| Valerius, NH | 2 |
| Burdge, DR | 1 |
| Nakielna, EM | 1 |
| Rabin, HR | 3 |
| Kureishi, A | 1 |
| Diver, JM | 2 |
| Beckthold, B | 1 |
| Schollaardt, T | 3 |
| Bryan, LE | 3 |
| Parker, AC | 1 |
| Preston, T | 1 |
| Heaf, D | 1 |
| Kitteringham, NR | 1 |
| Choonara, I | 1 |
| Giwercman, B | 1 |
| Saux, P | 1 |
| Martin, C | 1 |
| Mallet, MN | 1 |
| Papazian, L | 1 |
| Bruguerolle, B | 1 |
| De Micco, P | 1 |
| Gouin, F | 1 |
| Camp, KA | 1 |
| Miyagi, SL | 1 |
| Schroeder, DJ | 1 |
| Taylor, RF | 1 |
| Hodson, ME | 7 |
| Sheldon, CD | 1 |
| Assoufi, BK | 1 |
| Orenstein, DM | 2 |
| Pattishall, EN | 2 |
| Noyes, BE | 1 |
| Kurland, G | 1 |
| Hartigan, ER | 1 |
| Yu, VL | 1 |
| Sollich, V | 2 |
| Klöditz, E | 1 |
| Schuster, R | 1 |
| Handrick, W | 1 |
| Brömme, S | 1 |
| Rumler, W | 1 |
| Patsch, R | 1 |
| Kharari, H | 1 |
| Spencker, FB | 1 |
| Samuelson, WM | 1 |
| Pleasants, RA | 1 |
| Whitaker, MS | 1 |
| Vazquez, C | 1 |
| Municio, M | 1 |
| Corera, M | 1 |
| Gaztelurrutia, L | 1 |
| Sojo, A | 1 |
| Vitoria, JC | 1 |
| Lantner, RR | 1 |
| Schaefer, HG | 1 |
| Wedgwood, J | 4 |
| Hampel, B | 3 |
| Fischer, C | 1 |
| Kuhlmann, J | 1 |
| Schaad, UB | 6 |
| Campos, J | 1 |
| Román, F | 1 |
| Georgiou, M | 1 |
| García, C | 1 |
| Gómez-Lus, R | 1 |
| Escobar, H | 1 |
| Church, DA | 2 |
| Kanga, JF | 1 |
| Kuhn, RJ | 2 |
| Rubio, TT | 4 |
| Spohn, WA | 1 |
| Stevens, JC | 1 |
| Painter, BG | 1 |
| Thurberg, BE | 1 |
| Haverstock, DC | 1 |
| Perroncel, RY | 1 |
| Echols, RM | 2 |
| Ruedeberg, A | 1 |
| Kraemer, R | 2 |
| Miles, MV | 1 |
| Lettieri, JT | 1 |
| Warren, RW | 1 |
| Jick, S | 1 |
| Hullmann, R | 1 |
| Schmidt, H | 1 |
| Weber, A | 2 |
| Morlin, G | 1 |
| Cohen, M | 1 |
| Williams-Warren, J | 2 |
| Ramsey, B | 1 |
| Smith, A | 1 |
| Richard, DA | 1 |
| Nousia-Arvanitakis, S | 1 |
| Hampel, BJ | 1 |
| Sommerauer, B | 1 |
| Kapranov, NI | 4 |
| Kashirskaia, NIu | 1 |
| Belousov, IuB | 1 |
| Richards, RM | 1 |
| Hamilton, VE | 1 |
| Thomas, MR | 1 |
| Rey, E | 1 |
| Tréluyer, JM | 1 |
| Bonacorsi, S | 1 |
| Fitoussi, F | 1 |
| Lhopital, S | 1 |
| Bingen, E | 2 |
| Wu, YL | 1 |
| Scott, EM | 4 |
| Po, AL | 1 |
| Tariq, VN | 1 |
| Redmond, A | 1 |
| Sweeney, L | 1 |
| MacFarland, M | 1 |
| Mitchell, M | 1 |
| Daggett, S | 1 |
| Kubin, R | 1 |
| Jaffé, A | 1 |
| Bush, A | 1 |
| Jalal, S | 1 |
| Hoiby, N | 1 |
| Gotoh, N | 1 |
| Wretlind, B | 1 |
| Perederko, LV | 1 |
| Polikarpova, SV | 1 |
| Bald, M | 1 |
| Nikolaizik, W | 1 |
| Wingen, AM | 1 |
| Montgomery, MJ | 1 |
| Beringer, PM | 1 |
| Aminimanizani, A | 1 |
| Louie, SG | 1 |
| Shapiro, BJ | 1 |
| Jelliffe, R | 1 |
| Gill, MA | 1 |
| Marchetti, F | 1 |
| Candusso, M | 1 |
| Faraguna, D | 1 |
| Assael, BM | 1 |
| Postnikov, CC | 1 |
| Semiakin, SI | 1 |
| Griese, M | 1 |
| Müller, I | 1 |
| Reinhardt, D | 1 |
| Gillespie, T | 1 |
| Masterton, RG | 1 |
| Kumar, A | 2 |
| Hay, MB | 1 |
| Maier, GA | 1 |
| Dyke, JW | 1 |
| Denamur, E | 1 |
| Picard, B | 1 |
| Goullet, P | 1 |
| Lambert-Zechovsky, N | 1 |
| Foucaud, P | 1 |
| Navarro, J | 1 |
| Elion, J | 1 |
| Sander, E | 1 |
| Schaffner, T | 1 |
| Christensson, BA | 1 |
| Nilsson-Ehle, I | 2 |
| Ljungberg, B | 2 |
| Lindblad, A | 2 |
| Malmborg, AS | 2 |
| Hjelte, L | 2 |
| Strandvik, B | 2 |
| Hurley, JC | 1 |
| Williams, T | 1 |
| Thorson, C | 1 |
| O'Mahony, MS | 1 |
| FitzGerald, MX | 1 |
| Dostal, RE | 1 |
| Seale, JP | 1 |
| Yan, BJ | 1 |
| Drusano, GL | 1 |
| Hodges, NA | 1 |
| Gordon, CA | 1 |
| Ferguson, MI | 1 |
| Collier, PS | 4 |
| Evans, DJ | 1 |
| Allison, DG | 1 |
| Brown, MR | 1 |
| Gilbert, P | 1 |
| LeBel, M | 3 |
| Mack, G | 1 |
| Cooper, PJ | 1 |
| Buchanan, N | 1 |
| Stoupis, C | 1 |
| Tschaeppeler, H | 1 |
| Vock, P | 1 |
| Taylor, DM | 1 |
| Flowers, MK | 1 |
| Miller, MS | 1 |
| Gaido, F | 1 |
| Rourk, MH | 1 |
| Spock, A | 1 |
| Bosso, JA | 4 |
| Saxon, BA | 1 |
| Matsen, JM | 2 |
| Ansorg, R | 1 |
| Müller, KD | 1 |
| Wiora, J | 1 |
| Mimeault, J | 1 |
| Vallée, F | 2 |
| Seelmann, R | 1 |
| Sörgel, F | 1 |
| Ruel, M | 1 |
| Chamberland, S | 1 |
| Malouin, F | 1 |
| Parr, TR | 1 |
| Akaniro, JC | 1 |
| Vidaurre, CE | 1 |
| Stutman, HR | 3 |
| Marks, MI | 3 |
| Ball, P | 1 |
| Nixon, PA | 1 |
| Ross, EA | 1 |
| Kaplan, RM | 1 |
| Winrow, AP | 1 |
| Supramaniam, G | 1 |
| Fulton, B | 1 |
| Moore, LL | 1 |
| Black, A | 1 |
| Redmond, AO | 2 |
| Steen, HJ | 2 |
| Oborska, IT | 1 |
| Croize, J | 1 |
| Gout, JP | 1 |
| Robert, J | 1 |
| Le Noc, P | 1 |
| Wedgwood-Krucko, J | 1 |
| Guenin, K | 1 |
| Buehlmann, U | 1 |
| Stevenson, MI | 2 |
| Black, AE | 1 |
| Bayer, AS | 1 |
| Jawad, AS | 1 |
| Wofford-McQueen, R | 1 |
| Gordon, RC | 1 |
| Roberts, CM | 2 |
| Batten, J | 1 |
| Scully, BE | 4 |
| Neu, HC | 6 |
| Parry, MF | 1 |
| Mandell, W | 1 |
| Smith, MJ | 3 |
| Batten, JC | 3 |
| Butland, RJ | 1 |
| Salh, B | 1 |
| Webb, AK | 1 |
| Vellend, H | 1 |
| Kurz, CC | 1 |
| Marget, W | 1 |
| Harms, K | 1 |
| Bertele, RM | 1 |
| Goldfarb, J | 2 |
| Wormser, GP | 1 |
| Inchiosa, MA | 1 |
| Guideri, G | 1 |
| Diaz, M | 1 |
| Gandhi, R | 1 |
| Goltzman, C | 1 |
| Mascia, AV | 1 |
| Bergeron, MG | 1 |
| Fiset, C | 1 |
| Chassé, G | 1 |
| Bigonesse, P | 1 |
| Rivard, G | 1 |
| Shapiro, C | 1 |
| Alfaham, M | 1 |
| Holt, ME | 1 |
| Goodchild, MC | 2 |
| Figueredo, VM | 1 |
| Klinger, JD | 1 |
| Aronoff, SC | 1 |
| Walker, KB | 1 |
| Reed, MD | 2 |
| Stern, RC | 2 |
| Myers, CM | 2 |
| Yamashita, TS | 2 |
| Blumer, JL | 2 |
| Willems, FT | 1 |
| Haverman, FE | 1 |
| van den Broek, PJ | 1 |
| Bakker, W | 1 |
| Mattie, H | 1 |
| van Gulpen, C | 1 |
| Hvidberg, EF | 1 |
| Nielsen, CH | 1 |
| Greenwood, R | 1 |
| Chartrand, SA | 2 |
| Hilman, BC | 2 |
| Black, PG | 1 |
| Nakatomi, M | 1 |
| Ores, C | 1 |
| Davidson, S | 1 |
| Jules, K | 1 |
| Chin, NX | 1 |
| Davis, RL | 1 |
| Koup, JR | 1 |
| Heggen, L | 1 |
| Stempel, D | 1 |
| Smith, AL | 1 |
| Raeburn, JA | 1 |
| Govan, JR | 1 |
| McCrae, WM | 1 |
| Greening, AP | 1 |
| White, LO | 1 |
| Bowyer, H | 1 |
| Willis, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Role of Pseudomonas Aeruginosa Biofilms in Exacerbations in Patients With Bronchiectasis With and Without Chronic Obstructive Pulmonary Disease[NCT04803695] | 96 participants (Anticipated) | Observational | 2018-03-01 | Recruiting | |||
| Longitudinal Assessment of Risk Factors For and Impact of Pseudomonas Aeruginosa Acquisition and Early Anti-Pseudomonal Treatment in Children With CF[NCT00676169] | 1,248 participants (Actual) | Observational | 2004-10-31 | Completed | |||
| Effectiveness and Safety of Intermittent Antimicrobial Therapy for the Treatment of New Onset Pseudomonas Aeruginosa Airway Infection in Young Patients With Cystic Fibrosis[NCT00097773] | Phase 2 | 304 participants (Actual) | Interventional | 2004-09-30 | Completed | ||
| Prospective Randomized Trial Comparing Oral Ciproxin Plus Inhaled Colistin With Tobramycin for Inhalation for Eradication of P Aeruginosa Infection in Children With Cystic Fibrosis.[NCT01400750] | Phase 4 | 61 participants (Actual) | Interventional | 2001-08-31 | Completed | ||
| Supplementary Oral Azithromycin in Treatment of Intermittent Pseudomonas Aeruginosa Colonization in CF-patients With Inhaled Colistin and Oral Ciprofloxacin; Postponing Next Isolate of Pseudomonas and Prevention of Chronic Infection. A Prospective, Double[NCT00411736] | Phase 4 | 45 participants (Actual) | Interventional | 2008-05-31 | Completed | ||
| Endobronchial Valve for Emphysema PalliatioN Trial (VENT) Cost-effectiveness Sub-Study[NCT00137956] | Phase 3 | 270 participants | Interventional | 2004-12-31 | Terminated | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The primary comparison is between the pooled culture-based group and the pooled cycled group. A secondary comparison is between the pooled ciprofloxacin group vs the pooled placebo group. Descriptive results are provided for the pooled treatment groups.~Participants are represented once in the cycled and culture-based therapy columns, and once in the cipro and placebo columns." (NCT00097773)
Timeframe: Measured over the 18 month study
| Intervention | number of participants (Number) |
|---|---|
| Cycled TIS | 24 |
| Culture-Based TIS | 26 |
| Oral Ciprofloxacin | 29 |
| Oral Placebo | 21 |
"The primary comparison is between the pooled culture-based group and the pooled cycled group. No interactions with ciprofloxacin were identified. A secondary comparison is between the pooled ciprofloxacin group vs the pooled placebo group. Descriptive results are provided for the pooled treatment groups.~Participants are represented once in the cycled and culture-based therapy columns, and once in the cipro and placebo columns." (NCT00097773)
Timeframe: Measured over the 18 month time period
| Intervention | participants (Number) |
|---|---|
| Cycled TIS | 70 |
| Culture-Based TIS | 81 |
| Oral Ciprofloxacin | 83 |
| Oral Placebo | 68 |
"Proportion of participants with a Pa positive culture compared between (1) the pooled cycled therapy group (n=152) and pooled culture-based therapy group (n=152), and (2) between the pooled oral placebo (n=152)and pooled cipro groups (n=152).~Participants are included once in the cycled and culture-based columns, and once in the oral cipro and placebo columns" (NCT00097773)
Timeframe: Week 10 (after initial treatment course for Pa) through Month 18
| Intervention | Participants (Number) | ||||
|---|---|---|---|---|---|
| No Pa positive cultures | 1 Pa positive culture | 2 Pa positive cultures | 3 or more Pa positive cultures | Missing | |
| Culture-Based TIS | 85 | 38 | 18 | 9 | 2 |
| Cycled TIS | 109 | 17 | 9 | 13 | 4 |
| Oral Cipro | 97 | 22 | 13 | 14 | 6 |
| Oral Placebo | 97 | 33 | 14 | 8 | 0 |
23 reviews available for ciprofloxacin and Cystic Fibrosis
| Article | Year |
|---|---|
Developing ciprofloxacin dry powder for inhalation: A story of challenges and rational design in the treatment of cystic fibrosis lung infection.
Topics: Administration, Inhalation; Ciprofloxacin; Cystic Fibrosis; Humans; Lung; Powders | 2022 |
Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis.
Topics: Anti-Bacterial Agents; Azithromycin; Ceftazidime; Child; Child, Preschool; Ciprofloxacin; Colistin; | 2023 |
State of the art in cystic fibrosis pharmacology-Optimization of antimicrobials in the treatment of cystic fibrosis pulmonary exacerbations: I. Anti-methicillin-resistant Staphylococcus aureus (MRSA) antibiotics.
Topics: Aminoglycosides; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Ciprofloxacin; Clindamycin; Cys | 2020 |
Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis.
Topics: Administration, Inhalation; Administration, Oral; Adult; Anti-Bacterial Agents; Child; Ciprofloxacin | 2017 |
Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis.
Topics: Administration, Inhalation; Administration, Oral; Adult; Anti-Bacterial Agents; Child; Ciprofloxacin | 2014 |
Managing Pseudomonas aeruginosa respiratory infections in cystic fibrosis.
Topics: Administration, Inhalation; Administration, Oral; Anti-Bacterial Agents; Chronic Disease; Ciprofloxa | 2015 |
Liposomes for Pulmonary Drug Delivery: The Role of Formulation and Inhalation Device Design.
Topics: Animals; Ciprofloxacin; Cystic Fibrosis; Drug Carriers; Drug Compounding; Drug Delivery Systems; Dru | 2017 |
Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis.
Topics: Administration, Inhalation; Administration, Oral; Adult; Anti-Bacterial Agents; Child; Ciprofloxacin | 2009 |
Inhaled antibiotics for lower respiratory tract infections: focus on ciprofloxacin.
Topics: Administration, Inhalation; Animals; Anti-Bacterial Agents; Bronchiectasis; Ciprofloxacin; Clinical | 2012 |
Inhaled antibiotics in cystic fibrosis: what's new?
Topics: Administration, Inhalation; Adolescent; Amikacin; Anti-Bacterial Agents; Aztreonam; Child; Child, Pr | 2012 |
Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: III. fluoroquinolones.
Topics: Administration, Oral; Anti-Bacterial Agents; Ciprofloxacin; Cystic Fibrosis; Disease Progression; Dr | 2013 |
Eradication of early Pseudomonas aeruginosa infection.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Chronic Disease; Ciprofloxacin; Colistin; Cystic Fibro | 2005 |
Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients.
Topics: Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Bronchopneumonia; Cefepime; Ceftazidime; Cep | 2005 |
Fluoroquinolones in the treatment of cystic fibrosis.
Topics: Ciprofloxacin; Cystic Fibrosis; Drug Therapy, Combination; Humans; Ofloxacin; Pseudomonas Infections | 1993 |
Cystic fibrosis and endobronchial pseudomonas infection.
Topics: Bronchial Diseases; Burkholderia cepacia; Child; Ciprofloxacin; Cystic Fibrosis; Humans; Lung Transp | 1993 |
Potential quinolone-induced cartilage toxicity in children.
Topics: Anti-Infective Agents; Cartilage; Child; Child, Preschool; Ciprofloxacin; Clinical Trials as Topic; | 1994 |
Rheumatologic aspects of pediatric cystic fibrosis patients treated with fluoroquinolones.
Topics: Animals; Anti-Infective Agents; Arthralgia; Arthritis; Child; Ciprofloxacin; Cystic Fibrosis; Humans | 1997 |
Ciprofloxacin in pediatrics: worldwide clinical experience based on compassionate use--safety report.
Topics: Administration, Oral; Anti-Infective Agents; Arthralgia; Child; Ciprofloxacin; Clinical Trials as To | 1997 |
Drug disposition in cystic fibrosis.
Topics: Absorption; Anti-Infective Agents; Ciprofloxacin; Cloxacillin; Cyclosporine; Cystic Fibrosis; Flerox | 1998 |
Fluoroquinolones in the treatment of cystic fibrosis: a critical appraisal.
Topics: Adolescent; Adult; Anti-Infective Agents; Child; Ciprofloxacin; Cystic Fibrosis; Drug Resistance, Mi | 1991 |
Emergent resistance to ciprofloxacin amongst Pseudomonas aeruginosa and Staphylococcus aureus: clinical significance and therapeutic approaches.
Topics: Ciprofloxacin; Cystic Fibrosis; Drug Resistance, Microbial; Humans; Osteomyelitis; Pseudomonas aerug | 1990 |
Clinical efficacy of ciprofloxacin in lower respiratory tract infections.
Topics: Ciprofloxacin; Clinical Trials as Topic; Cystic Fibrosis; Drug Interactions; Humans; Lung Diseases, | 1989 |
Clinical utility of new quinolones in treatment of osteomyelitis and lower respiratory tract infections.
Topics: Animals; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Cross Infection; Cystic Fibrosi | 1989 |
45 trials available for ciprofloxacin and Cystic Fibrosis
| Article | Year |
|---|---|
Tolerability and pharmacokinetic properties of ciprofloxacin dry powder for inhalation in patients with cystic fibrosis: a phase I, randomized, dose-escalation study.
Topics: Administration, Inhalation; Adult; Anti-Bacterial Agents; Ciprofloxacin; Cystic Fibrosis; Drug Admin | 2013 |
Safety and pharmacokinetics of ciprofloxacin dry powder for inhalation in cystic fibrosis: a phase I, randomized, single-dose, dose-escalation study.
Topics: Administration, Inhalation; Adolescent; Adult; Anti-Bacterial Agents; Chemistry, Pharmaceutical; Cip | 2015 |
Ciprofloxacin during upper respiratory tract infections to reduce Pseudomonas aeruginosa infection in paediatric cystic fibrosis: a pilot study.
Topics: Administration, Oral; Adolescent; Anti-Bacterial Agents; Child; Child, Preschool; Ciprofloxacin; Cys | 2015 |
Early anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'.
Topics: Age Factors; Anti-Bacterial Agents; Child; Child, Preschool; Ciprofloxacin; Cohort Studies; Cystic F | 2009 |
Early anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'.
Topics: Age Factors; Anti-Bacterial Agents; Child; Child, Preschool; Ciprofloxacin; Cohort Studies; Cystic F | 2009 |
Early anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'.
Topics: Age Factors; Anti-Bacterial Agents; Child; Child, Preschool; Ciprofloxacin; Cohort Studies; Cystic F | 2009 |
Early anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'.
Topics: Age Factors; Anti-Bacterial Agents; Child; Child, Preschool; Ciprofloxacin; Cohort Studies; Cystic F | 2009 |
Antibiotic therapy and fat digestion and absorption in cystic fibrosis.
Topics: Adolescent; Adult; Amikacin; Anti-Bacterial Agents; Breath Tests; Ceftazidime; Child; Ciprofloxacin; | 2011 |
Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis.
Topics: Anti-Bacterial Agents; Child; Child, Preschool; Ciprofloxacin; Cystic Fibrosis; Female; Humans; Male | 2012 |
Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis.
Topics: Administration, Inhalation; Administration, Oral; Anti-Bacterial Agents; Anti-Infective Agents; Chil | 2011 |
Early antibiotic treatment for Pseudomonas aeruginosa eradication in patients with cystic fibrosis: a randomised multicentre study comparing two different protocols.
Topics: Administration, Inhalation; Administration, Oral; Anti-Bacterial Agents; Chi-Square Distribution; Ch | 2012 |
Comparison of two treatment regimens for eradication of Pseudomonas aeruginosa infection in children with cystic fibrosis.
Topics: Administration, Inhalation; Adolescent; Anti-Bacterial Agents; Anti-Infective Agents; Child; Child, | 2013 |
[On fluoroquinolones treatment safety in children (clinical, morphological and catamnesis data)].
Topics: Adolescent; Age Factors; Anemia, Aplastic; Anti-Infective Agents; Body Height; Cartilage; Child; Chi | 2002 |
Inhibition of caffeine metabolism by ciprofloxacin in children with cystic fibrosis as measured by the caffeine breath test.
Topics: Adolescent; Breath Tests; Caffeine; Carbon Dioxide; Child; Child, Preschool; Ciprofloxacin; Cystic F | 1994 |
Regular three monthly oral ciprofloxacin in adult cystic fibrosis patients infected with Pseudomonas aeruginosa.
Topics: Administration, Oral; Adult; Chronic Disease; Ciprofloxacin; Cystic Fibrosis; Double-Blind Method; D | 1993 |
[Oral ciprofloxacin therapy in juvenile patients with cystic fibrosis--results of a prospective pilot study].
Topics: Adolescent; Bacterial Infections; Child; Ciprofloxacin; Cystic Fibrosis; Dose-Response Relationship, | 1993 |
Early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis.
Topics: Adolescent; Aerosols; Bronchial Diseases; Child; Child, Preschool; Chronic Disease; Ciprofloxacin; C | 1993 |
Pharmacokinetics of ciprofloxacin in pediatric cystic fibrosis patients.
Topics: Administration, Oral; Adolescent; Aging; Anti-Infective Agents; Biotransformation; Blood Proteins; B | 1996 |
Sequential ciprofloxacin therapy in pediatric cystic fibrosis: comparative study vs. ceftazidime/tobramycin in the treatment of acute pulmonary exacerbations. The Cystic Fibrosis Study Group.
Topics: Acute Disease; Adolescent; Anti-Infective Agents; Arthralgia; Ceftazidime; Child; Child, Preschool; | 1997 |
Ciprofloxacin as antipseudomonal treatment in patients with cystic fibrosis.
Topics: Adolescent; Adult; Amikacin; Anti-Infective Agents; Ceftazidime; Child; Ciprofloxacin; Cystic Fibros | 1997 |
Pharmacokinetic disposition of sequential intravenous/oral ciprofloxacin in pediatric cystic fibrosis patients with acute pulmonary exacerbation.
Topics: Acute Disease; Administration, Oral; Adolescent; Anti-Infective Agents; Biological Availability; Chi | 1997 |
Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Anti-Infective Agents; Carrier State; Child; Child, Presch | 1997 |
Oral ciprofloxacin vs. intravenous ceftazidime plus tobramycin in pediatric cystic fibrosis patients: comparison of antipseudomonas efficacy and assessment of safety with ultrasonography and magnetic resonance imaging. Cystic Fibrosis Study Group.
Topics: Administration, Oral; Adolescent; Cartilage; Ceftazidime; Child; Child, Preschool; Ciprofloxacin; Cy | 1997 |
[Use of ciprofloxacin in children with mucoviscidosis].
Topics: Administration, Oral; Anti-Infective Agents; Child; Ciprofloxacin; Cystic Fibrosis; Female; Humans; | 1997 |
Oral ciprofloxacin in the treatment of pseudomonas exacerbations of paediatric cystic fibrosis: clinical efficacy and safety evaluation using magnetic resonance image scanning.
Topics: Administration, Oral; Adolescent; Adult; Anti-Infective Agents; Child; Ciprofloxacin; Cystic Fibrosi | 1998 |
[The efficacy and safety of ciprofloxacin in treating children with mucoviscidosis].
Topics: Adolescent; Anti-Infective Agents; Child; Child, Preschool; Ciprofloxacin; Cystic Fibrosis; Female; | 2000 |
Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis.
Topics: Adult; Anti-Infective Agents; Area Under Curve; Ciprofloxacin; Cystic Fibrosis; Female; Genotype; Ha | 2001 |
[Comparative yearly growth rate of children with mucoviscidosis treated and not treated with ciprofloxacin:clinicomorphological comparisons].
Topics: Adolescent; Anti-Infective Agents; Cartilage, Articular; Child; Child, Preschool; Ciprofloxacin; Cys | 2001 |
Eradication of initial Pseudomonas aeruginosa colonization in patients with cystic fibrosis.
Topics: Administration, Inhalation; Administration, Oral; Adolescent; Adult; Case-Control Studies; Ceftazidi | 2002 |
Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment.
Topics: Child; Child, Preschool; Chronic Disease; Ciprofloxacin; Colistin; Cystic Fibrosis; Drug Therapy, Co | 1991 |
Fluoroquinolones in the treatment of cystic fibrosis: a critical appraisal.
Topics: Adolescent; Adult; Anti-Infective Agents; Child; Ciprofloxacin; Cystic Fibrosis; Drug Resistance, Mi | 1991 |
Antipseudomonal therapy in cystic fibrosis: aztreonam and amikacin versus ceftazidime and amikacin administered intravenously followed by oral ciprofloxacin.
Topics: Adolescent; Adult; Amikacin; Aztreonam; Ceftazidime; Child; Child, Preschool; Ciprofloxacin; Cystic | 1989 |
Use of ciprofloxacin in cystic fibrosis patients.
Topics: Adult; Ciprofloxacin; Cystic Fibrosis; Drug Resistance, Microbial; Female; Humans; Lung Diseases; Ma | 1989 |
Clinical efficacy of ciprofloxacin in lower respiratory tract infections.
Topics: Ciprofloxacin; Clinical Trials as Topic; Cystic Fibrosis; Drug Interactions; Humans; Lung Diseases, | 1989 |
Oral ciprofloxacin compared with conventional intravenous treatment for Pseudomonas aeruginosa infection in adults with cystic fibrosis.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Azlocillin; Ciprofloxacin; Clinical Trials a | 1987 |
[A cross-over study on the effectiveness of ofloxacin and ciprofloxacin administered orally].
Topics: Administration, Oral; Adolescent; Adult; Anti-Infective Agents; Ciprofloxacin; Clinical Trials as To | 1986 |
Single-dose pharmacokinetics of oral ciprofloxacin in patients with cystic fibrosis.
Topics: Administration, Oral; Adolescent; Adult; Anti-Infective Agents; Ciprofloxacin; Cystic Fibrosis; Dose | 1986 |
Efficacy of oral fluoroquinolones versus conventional intravenous antipseudomonal chemotherapy in treatment of cystic fibrosis.
Topics: Adult; Anti-Infective Agents; Chronic Disease; Ciprofloxacin; Clinical Trials as Topic; Cystic Fibro | 1987 |
Comparative pharmacokinetics of ciprofloxacin and ofloxacin in cystic fibrosis patients.
Topics: Adolescent; Adult; Anti-Infective Agents; Ciprofloxacin; Cystic Fibrosis; Double-Blind Method; Femal | 1987 |
The efficacy and safety of ciprofloxacin and ofloxacin in chronic Pseudomonas aeruginosa infection in cystic fibrosis.
Topics: Adolescent; Adult; Anti-Infective Agents; Ciprofloxacin; Cystic Fibrosis; Double-Blind Method; Drug | 1987 |
Pharmacokinetics of two dosage regimens of ciprofloxacin during a two-week therapeutic trial in patients with cystic fibrosis.
Topics: Adult; Ciprofloxacin; Clinical Trials as Topic; Cystic Fibrosis; Female; Humans; Kinetics; Male; Res | 1987 |
Ciprofloxacin monotherapy for acute pulmonary exacerbations of cystic fibrosis.
Topics: Adolescent; Adult; Ciprofloxacin; Clinical Trials as Topic; Cystic Fibrosis; Female; Humans; Kinetic | 1987 |
Ciprofloxacin versus tobramycin plus azlocillin in pulmonary exacerbations in adult patients with cystic fibrosis.
Topics: Adult; Anti-Bacterial Agents; Azlocillin; Bacterial Infections; Ciprofloxacin; Clinical Trials as To | 1987 |
Randomized study of two dosage regimens of ciprofloxacin for treating chronic bronchopulmonary infection in patients with cystic fibrosis.
Topics: Adolescent; Adult; Bronchopneumonia; Ciprofloxacin; Clinical Trials as Topic; Cystic Fibrosis; Femal | 1987 |
Ciprofloxacin: comparative data in cystic fibrosis.
Topics: Adolescent; Adult; Azlocillin; Ciprofloxacin; Clinical Trials as Topic; Cystic Fibrosis; Drug Therap | 1987 |
Ciprofloxacin therapy in cystic fibrosis.
Topics: Adolescent; Adult; Azlocillin; Child; Ciprofloxacin; Clinical Trials as Topic; Cystic Fibrosis; Drug | 1987 |
Treatment of serious infections with intravenous ciprofloxacin.
Topics: Administration, Oral; Adult; Aged; Arthritis, Infectious; Bacterial Infections; Ciprofloxacin; Clini | 1987 |
Pharmacokinetics of ciprofloxacin in cystic fibrosis.
Topics: Administration, Oral; Adolescent; Adult; Chromatography, High Pressure Liquid; Ciprofloxacin; Cystic | 1987 |
158 other studies available for ciprofloxacin and Cystic Fibrosis
| Article | Year |
|---|---|
Antimicrobial susceptibility and synergy studies of Burkholderia cepacia complex isolated from patients with cystic fibrosis.
Topics: Anti-Bacterial Agents; Burkholderia cepacia complex; Burkholderia Infections; Cystic Fibrosis; Drug | 2007 |
The thymidine-dependent small-colony-variant phenotype is associated with hypermutability and antibiotic resistance in clinical Staphylococcus aureus isolates.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Cystic Fibrosis; Drug Resistance, Bacterial; Humans; Micr | 2008 |
Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.
Topics: Anti-Bacterial Agents; Azithromycin; Bacterial Proteins; Biofilms; Cefepime; Cephalosporins; Ciprofl | 2009 |
Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
Topics: Aminoglycosides; Anti-Bacterial Agents; Bacterial Outer Membrane Proteins; Bacterial Proteins; beta- | 2009 |
Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system.
Topics: Cystic Fibrosis; DNA Repair; Drug Resistance, Bacterial; Humans; Microbial Sensitivity Tests; Mutati | 2009 |
Involvement of pmrAB and phoPQ in polymyxin B adaptation and inducible resistance in non-cystic fibrosis clinical isolates of Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Cystic Fibrosis; Drug Resistance, Multiple, Bacterial; Ge | 2009 |
In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis.
Topics: Aerosols; Anti-Bacterial Agents; Bacteria; Biofilms; Chronic Disease; Ciprofloxacin; Colony Count, M | 2010 |
Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
Topics: Bacterial Outer Membrane Proteins; Bacterial Proteins; beta-Lactamases; Cystic Fibrosis; Drug Resist | 2010 |
Effectiveness of different eradication treatment protocols for new-onset Pseudomonas aeruginosa in children with cystic fibrosis.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Child; Ciprofloxacin; Clinical Protocols; Cystic | 2022 |
LipNanoCar Technology - A Versatile and Scalable Technology for the Production of Lipid Nanoparticles.
Topics: Animals; Anti-Bacterial Agents; Caenorhabditis elegans; Ciprofloxacin; Cystic Fibrosis; Liposomes; N | 2022 |
Antibiotic allergy in children with cystic fibrosis: A retrospective case-control study.
Topics: Amikacin; Anti-Bacterial Agents; Azithromycin; Case-Control Studies; Ceftazidime; Child; Ciprofloxac | 2022 |
Impact of N-Acetylcysteine and Antibiotics Against Single and Dual Species Biofilms of Pseudomonas aeruginosa and Achromobacter xylosoxidans.
Topics: Acetylcysteine; Achromobacter denitrificans; Animals; Anti-Bacterial Agents; Aztreonam; Biofilms; Ca | 2022 |
Impact of N-Acetylcysteine and Antibiotics Against Single and Dual Species Biofilms of Pseudomonas aeruginosa and Achromobacter xylosoxidans.
Topics: Acetylcysteine; Achromobacter denitrificans; Animals; Anti-Bacterial Agents; Aztreonam; Biofilms; Ca | 2022 |
Impact of N-Acetylcysteine and Antibiotics Against Single and Dual Species Biofilms of Pseudomonas aeruginosa and Achromobacter xylosoxidans.
Topics: Acetylcysteine; Achromobacter denitrificans; Animals; Anti-Bacterial Agents; Aztreonam; Biofilms; Ca | 2022 |
Impact of N-Acetylcysteine and Antibiotics Against Single and Dual Species Biofilms of Pseudomonas aeruginosa and Achromobacter xylosoxidans.
Topics: Acetylcysteine; Achromobacter denitrificans; Animals; Anti-Bacterial Agents; Aztreonam; Biofilms; Ca | 2022 |
Impact of N-Acetylcysteine and Antibiotics Against Single and Dual Species Biofilms of Pseudomonas aeruginosa and Achromobacter xylosoxidans.
Topics: Acetylcysteine; Achromobacter denitrificans; Animals; Anti-Bacterial Agents; Aztreonam; Biofilms; Ca | 2022 |
Impact of N-Acetylcysteine and Antibiotics Against Single and Dual Species Biofilms of Pseudomonas aeruginosa and Achromobacter xylosoxidans.
Topics: Acetylcysteine; Achromobacter denitrificans; Animals; Anti-Bacterial Agents; Aztreonam; Biofilms; Ca | 2022 |
Impact of N-Acetylcysteine and Antibiotics Against Single and Dual Species Biofilms of Pseudomonas aeruginosa and Achromobacter xylosoxidans.
Topics: Acetylcysteine; Achromobacter denitrificans; Animals; Anti-Bacterial Agents; Aztreonam; Biofilms; Ca | 2022 |
Impact of N-Acetylcysteine and Antibiotics Against Single and Dual Species Biofilms of Pseudomonas aeruginosa and Achromobacter xylosoxidans.
Topics: Acetylcysteine; Achromobacter denitrificans; Animals; Anti-Bacterial Agents; Aztreonam; Biofilms; Ca | 2022 |
Impact of N-Acetylcysteine and Antibiotics Against Single and Dual Species Biofilms of Pseudomonas aeruginosa and Achromobacter xylosoxidans.
Topics: Acetylcysteine; Achromobacter denitrificans; Animals; Anti-Bacterial Agents; Aztreonam; Biofilms; Ca | 2022 |
The Effects of Antibiotic Combination Treatments on Pseudomonas aeruginosa Tolerance Evolution and Coexistence with Stenotrophomonas maltophilia.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Colistin; Cystic Fibrosis; Humans; Microbial Sensitivity Tests | 2022 |
The Effects of Antibiotic Combination Treatments on Pseudomonas aeruginosa Tolerance Evolution and Coexistence with Stenotrophomonas maltophilia.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Colistin; Cystic Fibrosis; Humans; Microbial Sensitivity Tests | 2022 |
The Effects of Antibiotic Combination Treatments on Pseudomonas aeruginosa Tolerance Evolution and Coexistence with Stenotrophomonas maltophilia.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Colistin; Cystic Fibrosis; Humans; Microbial Sensitivity Tests | 2022 |
The Effects of Antibiotic Combination Treatments on Pseudomonas aeruginosa Tolerance Evolution and Coexistence with Stenotrophomonas maltophilia.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Colistin; Cystic Fibrosis; Humans; Microbial Sensitivity Tests | 2022 |
Novel therapeutic approach for the treatment of cystic fibrosis based on freeze-dried tridrug microparticles to treat cystic fibrosis.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Ciprofloxacin; Cystic Fibrosis; Dry Powder Inhale | 2023 |
Determining effects of nitrate, arginine, and ferrous on antibiotic recalcitrance of clinical strains of Pseudomonas aeruginosa in biofilm-inspired alginate encapsulates.
Topics: Alginates; Amikacin; Anti-Bacterial Agents; Arginine; Biofilms; Ciprofloxacin; Cystic Fibrosis; Huma | 2023 |
Inhalable combination powder formulations of phage and ciprofloxacin for P. aeruginosa respiratory infections.
Topics: Administration, Inhalation; Aerosols; Anti-Bacterial Agents; Bacteriophages; Chemistry, Pharmaceutic | 2019 |
Genomic and phenotypic comparison of environmental and patient-derived isolates of
Topics: Anti-Bacterial Agents; Ceftazidime; Ciprofloxacin; Cystic Fibrosis; Drug Resistance, Bacterial; Envi | 2019 |
Spray-drying of inhalable, multifunctional formulations for the treatment of biofilms formed in cystic fibrosis.
Topics: Acetylcysteine; Administration, Inhalation; Animals; Anti-Bacterial Agents; Azithromycin; Biofilms; | 2019 |
Reclassification of CLSI criteria for ciprofloxacin and levofloxacin susceptibility against Pseudomonas aeruginosa: Implications for patients with cystic fibrosis (CF).
Topics: Anti-Bacterial Agents; Awareness; Ciprofloxacin; Cystic Fibrosis; Health Occupations; Humans; Levofl | 2020 |
Disruption of the extracellular polymeric network of Pseudomonas aeruginosa biofilms by alginate lyase enhances pathogen eradication by antibiotics.
Topics: Biofilms; Ciprofloxacin; Cystic Fibrosis; Drug Synergism; Polysaccharide-Lyases; Pseudomonas aerugin | 2021 |
Delafloxacin--A novel fluoroquinolone for the treatment of ciprofloxacin-resistant Pseudomonas aeruginosa in patients with cystic fibrosis.
Topics: Adult; Anti-Bacterial Agents; Ciprofloxacin; Cystic Fibrosis; Fluoroquinolones; Humans; Microbial Se | 2021 |
Testing of aerosolized ciprofloxacin nanocarriers on cystic fibrosis airway cells infected with P. aeruginosa biofilms.
Topics: Animals; Anti-Bacterial Agents; Biofilms; Ciprofloxacin; Cystic Fibrosis; Humans; Pseudomonas aerugi | 2021 |
Long-term coexistence of
Topics: Anti-Bacterial Agents; Ciprofloxacin; Cystic Fibrosis; Drug Resistance, Bacterial; Humans; Pseudomon | 2021 |
Dry powders for the inhalation of ciprofloxacin or levofloxacin combined with a mucolytic agent for cystic fibrosis patients.
Topics: Administration, Inhalation; Calorimetry, Differential Scanning; Chemistry, Pharmaceutical; Ciproflox | 2017 |
Ciprofloxacin-loaded PLGA nanoparticles against cystic fibrosis P. aeruginosa lung infections.
Topics: Animals; Cell Line; Ciprofloxacin; Cystic Fibrosis; Drug Carriers; Horses; Humans; Lactic Acid; Mucu | 2017 |
Ciprofloxacin-loaded lipid-core nanocapsules as mucus penetrating drug delivery system intended for the treatment of bacterial infections in cystic fibrosis.
Topics: Bacterial Infections; Ciprofloxacin; Cystic Fibrosis; Delayed-Action Preparations; Drug Carriers; Li | 2017 |
Antibiotic resistance evolution of Pseudomonas aeruginosa in cystic fibrosis patients (2010-2013).
Topics: Adolescent; Adult; Amikacin; Anti-Bacterial Agents; Ceftazidime; Child; Ciprofloxacin; Cystic Fibros | 2018 |
Fabrication of inhaled hybrid silver/ciprofloxacin nanoparticles with synergetic effect against Pseudomonas aeruginosa.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Biofilms; Chemical Engineering; Ciprofloxacin; Cy | 2018 |
Potential pathogenicity of Inquilinus limosus in a pediatric patient with cystic fibrosis.
Topics: Amikacin; Anti-Bacterial Agents; Child; Ciprofloxacin; Clindamycin; Cystic Fibrosis; Gram-Negative B | 2018 |
Development of self-emulsifying drug delivery systems (SEDDS) for ciprofloxacin with improved mucus permeating properties.
Topics: Animals; Anti-Bacterial Agents; Chemistry, Pharmaceutical; Ciprofloxacin; Cystic Fibrosis; Drug Deli | 2018 |
Unveiling the early events of Pseudomonas aeruginosa adaptation in cystic fibrosis airway environment using a long-term in vitro maintenance.
Topics: Adaptation, Physiological; Anti-Bacterial Agents; Bacterial Translocation; Biofilms; Ciprofloxacin; | 2018 |
Nebulized gentamicin in combination with systemic antibiotics for eradicating early Pseudomonas aeruginosa infection in children with cystic fibrosis.
Topics: Administration, Inhalation; Administration, Oral; Adolescent; Anti-Bacterial Agents; Child; Child, P | 2019 |
No benefit of longer eradication therapy of Pseudomonas aeruginosa primoinfections in pediatric cystic fibrosis.
Topics: Anti-Bacterial Agents; Child; Ciprofloxacin; Clinical Protocols; Cystic Fibrosis; Female; Humans; Ma | 2019 |
Alginate lyase immobilized chitosan nanoparticles of ciprofloxacin for the improved antimicrobial activity against the biofilm associated mucoid P. aeruginosa infection in cystic fibrosis.
Topics: Animals; Anti-Bacterial Agents; Biofilms; Chitosan; Ciprofloxacin; Cystic Fibrosis; Drug Liberation; | 2019 |
Bacteriophage PEV20 and Ciprofloxacin Combination Treatment Enhances Removal of Pseudomonas aeruginosa Biofilm Isolated from Cystic Fibrosis and Wound Patients.
Topics: Anti-Bacterial Agents; Biofilms; Biological Therapy; Cell Line; Ciprofloxacin; Combined Modality The | 2019 |
Topics: Anti-Bacterial Agents; Bronchoalveolar Lavage; Ceftazidime; Child, Preschool; Ciprofloxacin; Clavula | 2019 |
Current ciprofloxacin usage in children hospitalized in a referral hospital in Paris.
Topics: Adolescent; Anti-Bacterial Agents; Bacterial Infections; Child; Child, Preschool; Ciprofloxacin; Cys | 2013 |
Alginate lyase and ciprofloxacin co-immobilization on biopolymeric microspheres for cystic fibrosis treatment.
Topics: Biopolymers; Ciprofloxacin; Cystic Fibrosis; Enzymes, Immobilized; Humans; Hydrogen-Ion Concentratio | 2013 |
Formation of hydroxyl radicals contributes to the bactericidal activity of ciprofloxacin against Pseudomonas aeruginosa biofilms.
Topics: Anti-Bacterial Agents; Biofilms; Ciprofloxacin; Cystic Fibrosis; Humans; Hydroxyl Radical; Pseudomon | 2014 |
The tyrosine kinase BceF and the phosphotyrosine phosphatase BceD of Burkholderia contaminans are required for efficient invasion and epithelial disruption of a cystic fibrosis lung epithelial cell line.
Topics: Albumins; Anti-Bacterial Agents; Bacterial Adhesion; Burkholderia cepacia complex; Burkholderia Infe | 2015 |
Combatting bacterial infections by killing persister cells with mitomycin C.
Topics: Ampicillin; Animals; Anti-Bacterial Agents; Biofilms; Caenorhabditis elegans; Ciprofloxacin; Cross-L | 2015 |
Effective strategies for managing new Pseudomonas cultures in adults with cystic fibrosis.
Topics: Adolescent; Adult; Analysis of Variance; Anti-Bacterial Agents; Chi-Square Distribution; Ciprofloxac | 2015 |
Determination of ciprofloxacin and levofloxacin in human sputum collected from cystic fibrosis patients using microextraction by packed sorbent-high performance liquid chromatography photodiode array detector.
Topics: Anti-Bacterial Agents; Chromatography, High Pressure Liquid; Ciprofloxacin; Cystic Fibrosis; Humans; | 2015 |
Impairment of Pseudomonas aeruginosa Biofilm Resistance to Antibiotics by Combining the Drugs with a New Quorum-Sensing Inhibitor.
Topics: Amides; Anti-Bacterial Agents; Bacterial Adhesion; Biofilms; Ciprofloxacin; Colistin; Cystic Fibrosi | 2015 |
Multidrug-Resistant Pseudomonas aeruginosa Infection in a Child with Cystic Fibrosis.
Topics: Adolescent; Amikacin; Anti-Bacterial Agents; beta-Lactams; Ciprofloxacin; Cystic Fibrosis; Drug Hype | 2016 |
Optimization of ciprofloxacin complex loaded PLGA nanoparticles for pulmonary treatment of cystic fibrosis infections: Design of experiments approach.
Topics: Anti-Bacterial Agents; Biofilms; Chemistry, Pharmaceutical; Ciprofloxacin; Cystic Fibrosis; Drug Car | 2016 |
Sodium Nitrite Inhibits Killing of Pseudomonas aeruginosa Biofilms by Ciprofloxacin.
Topics: Anti-Bacterial Agents; Biofilms; Ciprofloxacin; Cystic Fibrosis; Microbial Sensitivity Tests; Pseudo | 2017 |
Individual pharmacokinetic variation leads to underdosing of ciprofloxacin in some cystic fibrosis patients.
Topics: Adult; Anti-Bacterial Agents; Breath Tests; Ciprofloxacin; Cystic Fibrosis; Cytochrome P-450 CYP3A; | 2017 |
Mutator genes giving rise to decreased antibiotic susceptibility in Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Cystic Fibrosis; DNA Repair; DNA Transposable Elements; DNA, B | 2008 |
Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience.
Topics: Administration, Inhalation; Administration, Oral; Adolescent; Adult; Anti-Bacterial Agents; Child; C | 2008 |
Implementation of European standards of care for cystic fibrosis--control and treatment of infection.
Topics: Administration, Inhalation; Adult; Anti-Bacterial Agents; Bacterial Infections; Burkholderia cepacia | 2009 |
The costs of treatment of early and chronic Pseudomonas aeruginosa infection in cystic fibrosis patients.
Topics: Adult; Anti-Bacterial Agents; Ceftazidime; Child, Preschool; Chronic Disease; Ciprofloxacin; Clavula | 2009 |
Inhalable antibiotic delivery using a dry powder co-delivering recombinant deoxyribonuclease and ciprofloxacin for treatment of cystic fibrosis.
Topics: Administration, Inhalation; Anti-Infective Agents; Ciprofloxacin; Cystic Fibrosis; Deoxyribonuclease | 2010 |
Fluctuations in phenotypes and genotypes within populations of Pseudomonas aeruginosa in the cystic fibrosis lung during pulmonary exacerbations.
Topics: Adult; Bacteriophages; Ciprofloxacin; Cystic Fibrosis; Drug Resistance, Bacterial; Genotype; Humans; | 2010 |
Approaches to measure the fitness of Burkholderia cepacia complex isolates.
Topics: Adult; Amino Acid Substitution; Anti-Bacterial Agents; Bacterial Proteins; Biofilms; Burkholderia ce | 2010 |
Co-spray-dried mannitol-ciprofloxacin dry powder inhaler formulation for cystic fibrosis and chronic obstructive pulmonary disease.
Topics: Administration, Inhalation; Anti-Infective Agents; Chemistry, Pharmaceutical; Ciprofloxacin; Cystic | 2010 |
Stationary biofilm growth normalizes mutation frequencies and mutant prevention concentrations in Pseudomonas aeruginosa from cystic fibrosis patients.
Topics: Anti-Bacterial Agents; Biofilms; Ceftazidime; Ciprofloxacin; Cystic Fibrosis; Drug Resistance, Bacte | 2011 |
Suboptimal ciprofloxacin dosing as a potential cause of decreased Pseudomonas aeruginosa susceptibility in children with cystic fibrosis.
Topics: Adolescent; Anti-Bacterial Agents; Child; Ciprofloxacin; Computer Simulation; Cystic Fibrosis; Dose- | 2010 |
Molecular characterization and phylogenetic analysis of quinolone resistance-determining regions (QRDRs) of gyrA, gyrB, parC and parE gene loci in viridans group streptococci isolated from adult patients with cystic fibrosis.
Topics: Adult; Anti-Bacterial Agents; Ciprofloxacin; Cystic Fibrosis; DNA Gyrase; DNA Topoisomerase IV; DNA, | 2011 |
Economic effects of an eradication protocol for first appearance of Pseudomonas aeruginosa in cystic fibrosis patients: 1995 vs. 2009.
Topics: Administration, Oral; Adolescent; Anti-Bacterial Agents; Anti-Infective Agents; Burkholderia cepacia | 2011 |
Chronic desensitization to quinolones in fixed drug eruption.
Topics: Adult; Ciprofloxacin; Cystic Fibrosis; Desensitization, Immunologic; Drug Eruptions; Erythema; Femal | 2011 |
Mannitol-guided delivery of Ciprofloxacin in artificial cystic fibrosis mucus model.
Topics: Administration, Inhalation; Anti-Infective Agents; Ciprofloxacin; Cystic Fibrosis; Drug Carriers; Hu | 2011 |
What have we learned about early treatment of Pseudomonas aeruginosa infection in infants and children with cystic fibrosis?
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Cystic Fibrosis; Female; Humans; Male; | 2011 |
[Investigation of plasmid-mediated quinolone resistance in Pseudomonas aeruginosa strains isolated from cystic fibrosis patients].
Topics: Anti-Infective Agents; Ciprofloxacin; Cystic Fibrosis; Drug Resistance, Bacterial; Humans; Microbial | 2011 |
In vitro activities of the novel ceragenin CSA-13, alone or in combination with colistin, tobramycin, and ciprofloxacin, against Pseudomonas aeruginosa strains isolated from cystic fibrosis patients.
Topics: Ciprofloxacin; Colistin; Cystic Fibrosis; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combin | 2011 |
Effect of antibiotic treatment on fat absorption in mice with cystic fibrosis.
Topics: Animals; Anti-Bacterial Agents; Bile Acids and Salts; Body Weight; Ciprofloxacin; Cystic Fibrosis; C | 2012 |
In vitro prevention of Pseudomonas aeruginosa early biofilm formation with antibiotics used in cystic fibrosis patients.
Topics: Bacterial Typing Techniques; Biofilms; Ciprofloxacin; Cystic Fibrosis; Female; Humans; Levofloxacin; | 2012 |
Ciprofloxacin-induced phototoxicity in an adult cystic fibrosis population.
Topics: Adult; Anti-Infective Agents; Ciprofloxacin; Cystic Fibrosis; Dermatitis, Phototoxic; Female; Humans | 2012 |
Genomics of adaptation during experimental evolution of the opportunistic pathogen Pseudomonas aeruginosa.
Topics: Adaptation, Biological; Cell Culture Techniques; Ciprofloxacin; Cystic Fibrosis; Directed Molecular | 2012 |
Emerging antimicrobial resistances among Proteus mirabilis in Europe: report from the MYSTIC Program (1997-2001). Meropenem Yearly Susceptibility Test Information Collection.
Topics: Anti-Bacterial Agents; Cefepime; Ceftazidime; Cephalosporins; Ciprofloxacin; Critical Care; Cystic F | 2002 |
Use of the E test to assess synergy of antibiotic combinations against isolates of Burkholderia cepacia-complex from patients with cystic fibrosis.
Topics: Bacteriological Techniques; Burkholderia cepacia; Burkholderia Infections; Ceftazidime; Chi-Square D | 2003 |
Population pharmacokinetics of ciprofloxacin in pediatric patients.
Topics: Administration, Oral; Adolescent; Age Factors; Anti-Infective Agents; Biological Availability; Body | 2003 |
Survey of resistance of Pseudomonas aeruginosa from UK patients with cystic fibrosis to six commonly prescribed antimicrobial agents.
Topics: Adult; Anti-Bacterial Agents; Ceftazidime; Ciprofloxacin; Colistin; Cystic Fibrosis; Drug Resistance | 2003 |
Population pharmacokinetics of ciprofloxacin in pediatric and adolescent patients with acute infections.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Bayes Theorem; Body Weight; Child; Child, Pr | 2003 |
Reduction in prevalence of chronic Pseudomonas aeruginosa infection at a regional pediatric cystic fibrosis center.
Topics: Adolescent; Anti-Infective Agents; Child; Child, Preschool; Chronic Disease; Ciprofloxacin; Cystic F | 2004 |
Early interventions in CF.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Antibiotic Prophylaxis; Bronchoalveolar Lavage Fluid; | 2004 |
Antibody response to Pseudomonas aeruginosa in cystic fibrosis patients: a marker of therapeutic success?--A 30-year cohort study of survival in Danish CF patients after onset of chronic P. aeruginosa lung infection.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Antibodies, Bacterial; Child; Ciprofloxacin; Cohort St | 2004 |
Burkholderia cepacia genomovar III and Burkholderia vietnamiensis double infection in a cystic fibrosis child.
Topics: Amikacin; Anti-Infective Agents; Burkholderia; Burkholderia cepacia complex; Burkholderia Infections | 2002 |
Ciprofloxacin-induced renal insufficiency in cystic fibrosis.
Topics: Acute Kidney Injury; Adolescent; Adult; Anti-Infective Agents; Blood Urea Nitrogen; Ciprofloxacin; C | 2003 |
Risk factors for acquisition of methicillin-resistant Staphylococcus aureus (MRSA) by patients with cystic fibrosis.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Cephalosporins; Child; Child, Preschool; Chronic Disease; | 2005 |
Comparison of in vitro susceptibilities to levofloxacin and ciprofloxacin with Pseudomonas aeruginosa and Stenotrophomonas maltophilia isolated from cystic fibrosis patients in Northern Ireland.
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Child; Ciprofloxacin; Cystic Fibrosis; Female; | 2005 |
Microbiological rationale for the utilisation of prulifloxacin, a new fluoroquinolone, in the eradication of serious infections caused by Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Cystic Fibrosis; Dioxolanes; Drug Resistance, B | 2005 |
Eradication of small intestinal bacterial overgrowth in the cystic fibrosis mouse reduces mucus accumulation.
Topics: Animals; Anti-Infective Agents; Bacteria; Ciprofloxacin; Cystic Fibrosis; Cystic Fibrosis Transmembr | 2006 |
Moxifloxacin but not ciprofloxacin or azithromycin selectively inhibits IL-8, IL-6, ERK1/2, JNK, and NF-kappaB activation in a cystic fibrosis epithelial cell line.
Topics: Anti-Infective Agents; Aza Compounds; Azithromycin; Bronchi; Cell Line; Ciprofloxacin; Cystic Fibros | 2007 |
Coagulopathy in two patients with cystic fibrosis treated with ciprofloxacin.
Topics: Adolescent; Adult; Anti-Infective Agents; Blood Coagulation Disorders; Ciprofloxacin; Cystic Fibrosi | 2007 |
Altered transit and bacterial overgrowth in the cystic fibrosis mouse small intestine.
Topics: Animals; Ciprofloxacin; Cystic Fibrosis; Female; Gastric Emptying; Gastrointestinal Transit; Intesti | 2007 |
Successful recovery after disseminated infection due to mycobacterium abscessus in a lung transplant patient: subcutaneous nodule as first manifestation--a case report.
Topics: Acetamides; Adolescent; Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Cystic Fibrosis | 2007 |
Photosensitivity associated with ciprofloxacin use in adult patients with cystic fibrosis.
Topics: Adult; Ciprofloxacin; Cystic Fibrosis; Humans; Photosensitivity Disorders; Pseudomonas Infections | 1995 |
Cloning and nucleotide sequence of Pseudomonas aeruginosa DNA gyrase gyrA gene from strain PAO1 and quinolone-resistant clinical isolates.
Topics: Amino Acid Sequence; Anti-Infective Agents; Bacterial Proteins; Base Sequence; Ciprofloxacin; Clonin | 1994 |
Development of antibiotic resistance in Pseudomonas aeruginosa during two decades of antipseudomonal treatment at the Danish CF Center.
Topics: Anti-Bacterial Agents; beta-Lactamases; Carbenicillin; Ceftazidime; Ciprofloxacin; Cystic Fibrosis; | 1994 |
Penetration of ciprofloxacin into bronchial secretions from mechanically ventilated patients with nosocomial bronchopneumonia.
Topics: Aged; Bronchi; Bronchopneumonia; Chromatography, High Pressure Liquid; Ciprofloxacin; Cross Infectio | 1994 |
Cystic fibrosis: antibiotic prescribing practices in the United Kingdom and Eire.
Topics: Administration, Inhalation; Administration, Oral; Adult; Aminoglycosides; Anti-Bacterial Agents; Cef | 1993 |
Safety of ciprofloxacin in children with cystic fibrosis.
Topics: Administration, Oral; Adolescent; Alkaline Phosphatase; Child; Ciprofloxacin; Cystic Fibrosis; Drug | 1993 |
Arthropathy secondary to ciprofloxacin in an adult cystic fibrosis patient.
Topics: Adult; Ciprofloxacin; Cystic Fibrosis; Humans; Joint Diseases; Male | 1993 |
Ciprofloxacin desensitization in a patient with cystic fibrosis.
Topics: Administration, Oral; Adolescent; Ciprofloxacin; Cystic Fibrosis; Desensitization, Immunologic; Drug | 1995 |
Long-term persistence of ciprofloxacin-resistant Haemophilus influenzae in patients with cystic fibrosis.
Topics: Adult; Ampicillin Resistance; Anti-Infective Agents; beta-Lactamases; Chloramphenicol Resistance; Ci | 1996 |
Ciprofloxacin safety in a pediatric population.
Topics: Adolescent; Anti-Infective Agents; Chemical and Drug Induced Liver Injury; Child; Child, Preschool; | 1997 |
Ciprofloxacin use in pediatric and cystic fibrosis patients. Proceedings of a symposium. Nantucket, Massachusetts, July 28-29, 1995.
Topics: Anti-Infective Agents; Child; Ciprofloxacin; Cystic Fibrosis; Humans | 1997 |
Effect of nebulizer type and antibiotic concentration on device performance.
Topics: Aminoglycosides; Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Infections; Ceftazidime; Ci | 1997 |
In-vitro investigation of the antibacterial activity of agents which may be used for the oral treatment of lung infections in CF patients.
Topics: Administration, Oral; Anti-Bacterial Agents; Ciprofloxacin; Cystic Fibrosis; Drug Therapy, Combinati | 1998 |
Comparative in vitro activities of meropenem, imipenem, temocillin, piperacillin, and ceftazidime in combination with tobramycin, rifampin, or ciprofloxacin against Burkholderia cepacia isolates from patients with cystic fibrosis.
Topics: Burkholderia cepacia; Burkholderia Infections; Ceftazidime; Ciprofloxacin; Cystic Fibrosis; Drug Syn | 1999 |
Development of resistance and cross-resistance in Pseudomonas aeruginosa exposed to subinhibitory antibiotic concentrations.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Azlocillin; Ceftazidime; Cephalosporins; Ciprofloxacin | 1999 |
If you can't stand the rash, get out of the kitchen: an unusual adverse reaction to ciprofloxacin.
Topics: Anti-Infective Agents; Child; Ciprofloxacin; Cystic Fibrosis; Dermatitis, Photoallergic; Female; Hum | 1999 |
Molecular mechanisms of fluoroquinolone resistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
Topics: Adult; Anti-Infective Agents; Bacterial Outer Membrane Proteins; Bacterial Proteins; Ciprofloxacin; | 2000 |
[Comparative morphological analysis of the articular cartilage, epiphyseal plate, spongy bone, and synovial membrane of the knee joint in children treated and not treated with ciprofloxacin].
Topics: Adolescent; Anemia, Aplastic; Anti-Infective Agents; Bone and Bones; Cartilage, Articular; Child; Ci | 2000 |
Ciprofloxacin-induced acute renal failure in a patient with cystic fibrosis.
Topics: Acute Kidney Injury; Adolescent; Anti-Infective Agents; Ciprofloxacin; Creatinine; Cystic Fibrosis; | 2001 |
[Comparative efficacy and safety of ciprofloxacin, ofloxacin, and pefloxacin in treatment of respiratory infections in children with cystic fibrosis].
Topics: Adolescent; Anti-Infective Agents; Arthritis; Child; Child, Preschool; Ciprofloxacin; Cystic Fibrosi | 2001 |
Early Pseudomonas aeruginosa colonisation in cystic fibrosis patients.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Child; Ciprofloxacin; Clinical Trials as Topic; Coli | 2002 |
Investigation into the selection frequency of resistant mutants and the bacterial kill rate by levofloxacin and ciprofloxacin in non-mucoid Pseudomonas aeruginosa isolates from cystic fibrosis patients.
Topics: Adult; Anti-Infective Agents; Ciprofloxacin; Cystic Fibrosis; Dose-Response Relationship, Drug; Drug | 2002 |
Post-antibiotic effect of ceftazidime, ciprofloxacin, imipenem, piperacillin and tobramycin for Pseudomonas cepacia.
Topics: Burkholderia cepacia; Ceftazidime; Ciprofloxacin; Cystic Fibrosis; Humans; Imipenem; Microbial Sensi | 1992 |
Molecular epidemiological analysis of Pseudomonas aeruginosa strains causing failure of antibiotic therapy in cystic fibrosis patients.
Topics: Azlocillin; Bacterial Typing Techniques; Ceftazidime; Ciprofloxacin; Cystic Fibrosis; Drug Resistanc | 1992 |
Morphologic studies for skeletal toxicity after prolonged ciprofloxacin therapy in two juvenile cystic fibrosis patients.
Topics: Adolescent; Autopsy; Bone Diseases; Cartilage Diseases; Child; Ciprofloxacin; Cystic Fibrosis; Femal | 1992 |
Increased oral bioavailability of ciprofloxacin in cystic fibrosis patients.
Topics: Administration, Oral; Adolescent; Adult; Biological Availability; Ciprofloxacin; Cystic Fibrosis; Dr | 1992 |
Resistance to ciprofloxacin of respiratory pathogens in patients with cystic fibrosis.
Topics: Ciprofloxacin; Cystic Fibrosis; Drug Resistance, Microbial; Humans; Pseudomonas aeruginosa | 1992 |
Persistence mechanisms in Pseudomonas aeruginosa from cystic fibrosis patients undergoing ciprofloxacin therapy.
Topics: Bacterial Outer Membrane Proteins; beta-Lactamases; Carbon Radioisotopes; Chloramphenicol O-Acetyltr | 1991 |
Cystic fibrosis and seizures.
Topics: Adult; Ciprofloxacin; Cystic Fibrosis; Humans; Seizures; Theophylline | 1991 |
Resistance to ciprofloxacin of respiratory pathogens in patients with cystic fibrosis.
Topics: Adolescent; Adult; Child; Child, Preschool; Ciprofloxacin; Cystic Fibrosis; Dose-Response Relationsh | 1992 |
Optimal sampling theory and population modelling: application to determination of the influence of the microgravity environment on drug distribution and elimination.
Topics: Bayes Theorem; Ceftazidime; Chromatography, High Pressure Liquid; Ciprofloxacin; Cystic Fibrosis; Fe | 1991 |
Protection of Pseudomonas aeruginosa against ciprofloxacin and beta-lactams by homologous alginate.
Topics: Alginates; Anti-Bacterial Agents; beta-Lactams; Ciprofloxacin; Cystic Fibrosis; Humans; Microbial Se | 1991 |
Development of resistance to ciprofloxacin in nutrient-rich and nutrient-limited growth conditions in vitro by Pseudomonas aeruginosa isolates from patients with cystic fibrosis.
Topics: Cells, Cultured; Ciprofloxacin; Cystic Fibrosis; Drug Resistance, Microbial; Humans; Microbial Sensi | 1991 |
Susceptibility of Pseudomonas aeruginosa and Escherichia coli biofilms towards ciprofloxacin: effect of specific growth rate.
Topics: Bacteriological Techniques; Ciprofloxacin; Cystic Fibrosis; Drug Resistance, Microbial; Escherichia | 1991 |
Effects of enzyme supplementation on oral absorption of ciprofloxacin in patients with cystic fibrosis.
Topics: Administration, Oral; Adolescent; Adult; Ciprofloxacin; Cystic Fibrosis; Female; Humans; Intestinal | 1991 |
Clinical, radiologic and magnetic resonance monitoring for skeletal toxicity in pediatric patients with cystic fibrosis receiving a three-month course of ciprofloxacin.
Topics: Adolescent; Adult; Cartilage, Articular; Child; Ciprofloxacin; Cystic Fibrosis; Female; Humans; Join | 1991 |
Variable theophylline clearance in cystic fibrosis.
Topics: Adult; Ciprofloxacin; Cystic Fibrosis; Drug Interactions; Humans; Male; Metabolic Clearance Rate; Th | 1991 |
Anaphylactoid reactions to ciprofloxacin in cystic fibrosis patients.
Topics: Adolescent; Adult; Anaphylaxis; Child; Child, Preschool; Ciprofloxacin; Cystic Fibrosis; Female; Hum | 1991 |
In vitro activities of combinations of aztreonam, ciprofloxacin, and ceftazidime against clinical isolates of Pseudomonas aeruginosa and Pseudomonas cepacia from patients with cystic fibrosis.
Topics: Aztreonam; Ceftazidime; Ciprofloxacin; Cystic Fibrosis; Drug Therapy, Combination; Humans; Microbial | 1990 |
Comparison of inhibitory and bactericidal activity of antipseudomonal antibiotics against Pseudomonas aeruginosa isolates from cystic fibrosis patients.
Topics: Amikacin; Ciprofloxacin; Cystic Fibrosis; Drug Resistance, Microbial; Humans; Imipenem; Microbial Se | 1990 |
Altered disposition of fleroxacin in patients with cystic fibrosis.
Topics: Administration, Oral; Adolescent; Adult; Anti-Infective Agents; Ciprofloxacin; Cystic Fibrosis; Drug | 1990 |
Persistence of Pseudomonas aeruginosa during ciprofloxacin therapy of a cystic fibrosis patient: transient resistance to quinolones and protein F-deficiency.
Topics: Adult; Anti-Infective Agents; Antibodies, Monoclonal; Bacterial Outer Membrane Proteins; Chemical Ph | 1990 |
Comparative in vitro activity of a new quinolone, fleroxacin, against respiratory pathogens from patients with cystic fibrosis.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Bacteria; Ciprofloxacin; Cystic Fibrosis; Fleroxacin; | 1990 |
Quality of well-being before and after antibiotic treatment of pulmonary exacerbation in patients with cystic fibrosis.
Topics: Attitude to Health; Ciprofloxacin; Cystic Fibrosis; Humans; Pseudomonas Infections; Quality of Life; | 1990 |
Benign intracranial hypertension after ciprofloxacin administration.
Topics: Adolescent; Ciprofloxacin; Cystic Fibrosis; Female; Humans; Pseudotumor Cerebri | 1990 |
Comment: Ciprofloxacin excretion into breast milk.
Topics: Adolescent; Ciprofloxacin; Cystic Fibrosis; Female; Humans; Joint Diseases; Lactation; Milk, Human | 1990 |
Tolerance and safety of ciprofloxacin in paediatric patients.
Topics: Adolescent; Child; Child, Preschool; Ciprofloxacin; Cystic Fibrosis; Drug Evaluation; Female; Humans | 1990 |
[In vitro effect of various antibiotics: beta lactams, aminoglycosides and fluoroquinolones alone and in combination against P. aeruginosa isolated from patients with mucoviscidosis].
Topics: Aminoglycosides; Anti-Bacterial Agents; beta-Lactams; Ciprofloxacin; Cystic Fibrosis; Drug Resistanc | 1989 |
Clinical and pharmacokinetic aspects of ciprofloxacin in the treatment of acute exacerbations of pseudomonas infection in cystic fibrosis patients.
Topics: Administration, Oral; Adolescent; Adult; Chromatography, High Pressure Liquid; Ciprofloxacin; Cystic | 1989 |
Cystic fibrosis and drug-induced arthropathy.
Topics: Adolescent; Ciprofloxacin; Cystic Fibrosis; Female; Humans; Joint Diseases; Pseudomonas Infections | 1989 |
Comparison of efficacy and tolerance of intravenously and orally administered ciprofloxacin in cystic fibrosis patients with acute exacerbations of lung infection.
Topics: Administration, Oral; Adolescent; Adult; Biological Availability; Ciprofloxacin; Cystic Fibrosis; Dr | 1989 |
Ciprofloxacin, imipenem and rifampicin: in-vitro synergy of two and three drug combinations against Pseudomonas cepacia.
Topics: Ciprofloxacin; Cystic Fibrosis; Drug Synergism; Drug Therapy, Combination; Humans; Imipenem; Microbi | 1989 |
Ciprofloxacin-resistant Pseudomonas.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Cystic Fibrosis; Drug Resistance, Microbial; Humans; London; P | 1985 |
Oral ciprofloxacin therapy of infections due to Pseudomonas aeruginosa.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents, Urinary | 1986 |
Ciprofloxacin in cystic fibrosis.
Topics: Administration, Oral; Adolescent; Adult; Ciprofloxacin; Cystic Fibrosis; Female; Humans; Male; Pseud | 1986 |
Ciprofloxacin resistance.
Topics: Ciprofloxacin; Cystic Fibrosis; Drug Resistance, Microbial; Humans; Pseudomonas; Pseudomonas Infecti | 1987 |
Role of fluoroquinolones in lower respiratory tract infections.
Topics: Animals; Anti-Infective Agents; Bronchi; Bronchitis; Ciprofloxacin; Cystic Fibrosis; Gram-Negative B | 1989 |
Pharmacokinetics and pharmacodynamics of ciprofloxacin in cystic fibrosis patients.
Topics: Adult; Analysis of Variance; Body Fluids; Ciprofloxacin; Cystic Fibrosis; Drug Resistance, Microbial | 1986 |
Ciprofloxacin in the treatment of Pseudomonas infection in cystic fibrosis patients.
Topics: Adolescent; Adult; Azlocillin; Ciprofloxacin; Cystic Fibrosis; Drug Therapy, Combination; Humans; Ps | 1986 |
Arthropathy in a patient with cystic fibrosis taking ciprofloxacin.
Topics: Adolescent; Ciprofloxacin; Cystic Fibrosis; Female; Humans; Joint Diseases; Knee Joint; Pseudomonas | 1987 |
Synergy of ciprofloxacin with fosfomycin in vitro against Pseudomonas isolates from patients with cystic fibrosis.
Topics: Ciprofloxacin; Cystic Fibrosis; Drug Synergism; Fosfomycin; Humans; Microbial Sensitivity Tests; Pse | 1988 |
Effect of ciprofloxacin in an in-vitro pharmacokinetic model against Pseudomonas aeruginosa isolated during cystic fibrosis lung infection.
Topics: Ciprofloxacin; Cystic Fibrosis; Dose-Response Relationship, Drug; Humans; Models, Biological; Pseudo | 1988 |
In-vitro activity of ciprofloxacin and other antibacterial agents against Pseudomonas aeruginosa and Pseudomonas cepacia from cystic fibrosis patients.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Cystic Fibrosis; Humans; Microbial Sensitivity Tests; Pseudomo | 1985 |
Lack of correlation between objective indicators and clinical-response scores during antimicrobial therapy for acute pulmonary exacerbations of cystic fibrosis.
Topics: Anti-Bacterial Agents; Azlocillin; Aztreonam; Ciprofloxacin; Cystic Fibrosis; Humans; Tobramycin | 1988 |
Lack of unique ciprofloxacin pharmacokinetic characteristics in patients with cystic fibrosis.
Topics: Adolescent; Adult; Ciprofloxacin; Cystic Fibrosis; Female; Humans; Male; Pancreas; Sputum | 1988 |
Long-term oral ciprofloxacin therapy in a cystic fibrosis patient.
Topics: Administration, Oral; Adult; Ciprofloxacin; Cystic Fibrosis; Humans; Male; Pseudomonas Infections; T | 1988 |
The use of ciprofloxacin in the treatment of patients with cystic fibrosis.
Topics: Adult; Bacterial Infections; Ciprofloxacin; Cystic Fibrosis; Drug Resistance, Microbial; Haemophilus | 1987 |
Effect of ciprofloxacin on fecal flora of patients with cystic fibrosis and other patients treated with oral ciprofloxacin.
Topics: Administration, Oral; Adolescent; Adult; Aged; Bacterial Infections; Ciprofloxacin; Cystic Fibrosis; | 1987 |
Ciprofloxacin: an overview and prospective appraisal.
Topics: Administration, Oral; Animals; Bacterial Infections; Ciprofloxacin; Cystic Fibrosis; Disease Models, | 1987 |
Ciprofloxacin therapy in cystic fibrosis.
Topics: Adolescent; Adult; C-Reactive Protein; Child; Ciprofloxacin; Cystic Fibrosis; Humans; Pseudomonas In | 1987 |
Pharmacokinetics and sputum penetration of ciprofloxacin in patients with cystic fibrosis.
Topics: Adolescent; Adult; Ciprofloxacin; Cystic Fibrosis; Female; Humans; Kinetics; Male; Pseudomonas Infec | 1986 |